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ABSTRACT 
 
Inflammatory bowel disease (IBD) is an immunological imbalance of the gut, 
characterised by chronic inflammation involving the mucosal lining of the colon. IBD 
presents in two forms: Crohn’s disease (CD) and ulcerative colitis (UC). The increasing 
global incidence of IBD has necessitated a better understanding of the underlying 
mechanism of disease progression, and while its aetiology remains obscure, current 
literature suggests that both genetic susceptibility and environmental aspects have an 
influence on the course of IBD.  
Murine models have led to a number of discoveries in IBD pathogenesis. Amongst the 
many mouse models developed, the Winnie mouse model of colitis closely resembles the 
condition of human colitis in terms of both symptoms and immunology. A number of 
studies have reported that Winnie mice are a preclinical resource for better understanding 
IBD pathogenesis. An emerging mechanism for the pathogenicity of IBD development 
includes a dysregulated chemokine system. In particular, the CCR6-CCL20 axis has been 
implicated due to its major role in regulating T cell homeostasis in the intestine. The 
current literature regarding CCR6-CCL20 is inconclusive as to the exact role of CCR6.  
The aim of this study was to introduce CCR6 deficiency in the Winnie spontaneous colitis 
model in order to further elucidate the functional role of CCR6 in colitis and characterise 
clinical, histopathological and immunological changes.  
In this present study, the hypothesis was that the genetic ablation of the Ccr6 gene would 
exacerbate intestinal inflammation.  
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Winnie mice were backcrossed with Ccr6
-/- 
mice to generate Winnie mice with a Ccr6 
deficiency.
 
Winnie x Ccr6
-/-
 mice developed normally and did not have any 
developmental abnormalities. At around 8–12 weeks of age, the Winnie x Ccr6-/- mice 
were clinically assessed, and no significant differences were noted between Winnie and 
Winnie x Ccr6
-/-
 mice with regard to body weight. There was, however, a significant 
increase in the colon weight/body weight ratio (±0.026 mg/g), with Winnie x Ccr6
-/-
 mice 
revealing a significant increase in colon weight by body weight ratio compared to control 
mice (WT and Ccr6
-/-
 mice) of a similar magnitude to the expected Winnie-only 
phenotype. 
Histopathological examination of proximal and distal colonic sections showed no obvious 
inflammatory changes in the control mice (WT grade-0 and Ccr6
-/-
 grade-0). Winnie mice 
demonstrated the expected amount of inflammation in the distal colonic segment (grade-
6). Surprisingly, there was a differential distribution of inflammation in Winnie x Ccr6
-/-
 
mice, where the proximal colon revealed significant inflammation (grade-8) while there 
was mild inflammation (grade-4) in the distal colon. 
Immuno-phenotyping of splenocytes and colonic lymphocytes did not reveal any 
significant changes in the functions of T regulatory cells. To identify the differential 
regulation in Winnie x Ccr6
-/-
 mice, we cultured ex vivo colonic segments from Winnie, 
Winnie x Ccr6
-/-
, Ccr6
-/-
 and WT mice to assess the secretion of cytokines. Interestingly, 
molecular and cytokine assays demonstrated elevated levels of anti-inflammatory 
cytokine interleukin-10 (IL-10) in the distal colon and increased expression of pro-
inflammatory cytokine, interleukin-1β (IL-1β), in the proximal colon.  
In Winnie x Ccr6
-/- 
mice, an increased expression of IL-1β in the proximal colon 
correlated with an exacerbation of inflammation. Increased expression of anti-
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inflammatory cytokine IL-10 was associated with an amelioration of inflammation in the 
Winnie x Ccr6
-/-
 distal colon. These results suggest that absence of the Ccr6 gene 
selectively confers amelioration of colitis in the distal colon but exacerbation in the 
proximal colon.  
Overall, this study presents significant and novel findings in the CCR6-deficient 
spontaneous colitis model. Genetic ablation of Ccr6 conferred regional differential 
exacerbation between colonic segments of Winnie x Ccr6
-/- 
mice. Findings from this 
study reveal the hitherto unknown mechanism of Ccr6 differential distribution in the 
colon, thereby demonstrating an important role for CCR6 in the development of colitis. 
This will throw more light towards understanding the pathogenesis of colitis in IBD. 
These findings indicate that CCR6 could potentially serve as a diagnostic marker and a 
novel therapeutic target. 
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Chapter 1 
Introduction 
 
 
Inflammatory bowel disease (IBD) is an immune-mediated disorder characterised by 
lifelong, chronic intestinal inflammation [1-3]. Globally, IBD is highly prevalent among 
young adults and has a huge impact on their quality of life [4]. Australia has been 
reported as having the highest incidence of IBD: around 75,000 people are affected and 
this number is predicted to increase to 100,000 by the year 2022 [5]. In Australia, the 
economic burden of IBD is around 2.7 billion dollars every year. The onset of IBD occurs 
between the age of 5–40 in both men and women, affecting approximately 1 in 250 
people [6,7]. Epidemiological studies reveal that the high incidence and prevalence of 
IBD is now in a stabilised pattern in continents such as America and Australia, as well as 
in some European countries [8,9]. Additionally, an increase in the incidence of IBD has 
been observed in the last decade in some developing countries of Asia and Africa [8]. 
Such a change in IBD incidence may be attributed to factors such as westernisation of 
lifestyle, diet, increased consumption of foods high in sugar, improved hygiene and 
increased use of antibiotics [8]. Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two most common forms of IBD affecting the gastrointestinal tract [3]. CD is a 
transmural, granulomatous condition commonly involving the ileum and the colon. In 
contrast, UC specifically involves the colon of the intestine and manifests as superficial 
inflammation confined to the mucosal and submucosal layers of the intestinal wall [3,10]. 
Overlapping symptoms of CD and UC are chronic relapsing flares associated with rectal 
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bleeding, abdominal pain and/or diarrhoea [10,11]. Colorectal cancer and a toxic 
megacolon are life-threatening gastrointestinal complications of UC and CD patients 
[3,12,13]. Extra-intestinal manifestations such as musculoskeletal, dermatologic, 
hepatopancreatobiliary, ocular, renal and pulmonary manifestations were observed in 25–
40% of IBD patients [14].  
1.1 Crohn’s disease  
 
CD can affect any part of the gastrointestinal tract, from the mouth to the anus, but is 
most commonly localised to the ileum and the colon. CD is characterised by a transmural 
granulomatous inflammation affecting all layers of the intestinal wall. The inflamed 
regions demonstrate skip lesions, the presence of deep ulceration of bowel mucosa, 
perianal fistulas, rectal sparing, aphthous ulcers, and thickening of the intestinal wall [15-
17]. The symptoms of CD are persistent diarrhoea, abdominal pain and cramps, 
development of bowel strictures and discontinuous ulcers in the digestive tract. Treatment 
for CD is currently symptomatic with the use of aminosalicylates and immune modulators 
[18].   
1.2 Ulcerative colitis 
 
 UC is a disease of the colon which causes inflammation confined to the mucosal and 
submucosal layers of the intestinal wall [17]. UC manifests as frequent bouts of bloody 
diarrhoea, abdominal pain and cramps, and is associated with fever and loss of appetite. 
The inflammation is continuous and usually involves the rectum and part of the proximal 
colon or the entire colon [17]. Interestingly, early appendectomy and smoking confer 
beneficial effects in patients suffering from UC, but not in CD [19]. There is convincing 
evidence proving a lower incidence of UC in smokers and presentation of a milder 
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disease course than in non–smokers [20]. Surgical options for UC, such as colectomy, are 
reserved for complications such as fulminant colitis, toxic megacolon and 
dysplasia/colorectal cancer [21]. 
1.3 Pathogenesis of IBD 
 
The pathogenesis leading to the disease process has been widely researched, yet the 
detailed mechanisms remain elusive [22]. While the aetiology of IBD remains unclear, 
evidence suggests impaired innate and adaptive immune responses play a significant role 
in the initiation of IBD [4,23-25]. An altered immune response against luminal bacteria in 
genetically predisposed individuals is reported to be a primary risk factor for IBD (Figure 
1.1) [22]. Mucosal breaches by luminal microflora initiating an immune response that can 
be exacerbated by an altered balance between commensal and pathogenic bacteria are 
considered another risk factor [26].   
Environmental factors such as the use of antibiotics, smoking, westernised diet, 
psychological stress, appendectomy, oral contraceptives, antibiotics, atypical 
mycobacterial infection, episodes of childhood infections, and increased intestinal 
permeability can act as possible triggers for the initiation of IBD [4]. Mawdsley et al. [27] 
reported that psychological stress augments disease activity in IBD. In IBD patients, 
episodes of acute and chronic stress influence the immune mechanisms and may be 
relevant to the initiation of IBD pathogenesis.  
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Figure 1.1: Multiple factors contributing to the initiation of IBD. 
Genetic predisposition of individuals plays a major role in the initiation of IBD. Environmental 
factors and luminal microflora may act as triggers in the presence of a dysregulated immune 
response that exacerbates IBD.  
 
Genome-wide association studies (GWAS) have subsequently identified up to 71 new 
associations in addition to the existing loci, bringing the total to around 163 risk-
conferring loci associated with IBD [28]. Genetic susceptibility is one of the major 
contributing factors to the onset of IBD [29,30]. Numerous studies have identified genetic 
factors associated with IBD and have found that the overall expression appears to be 
polygenic [31]. GWAS have specifically shown new insights into the complex pathway 
of IBD pathogenesis [32].  
The first IBD susceptibility gene, identified using candidate gene studies, was mapped to 
chromosome 16 and was identified as nucleotide-binding oligomerization domain-
containing protein 2 (NOD2), also known as caspase recruitment domain-containing 
protein 15 (CARD15) [10,31]. The identification of the gene NOD2/CARD15 was pivotal 
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in providing a better understanding of IBD pathogenesis and emphasising a link between 
development and innate immunity [31]. The association between NOD2 mutations and 
CD is much stronger than with UC [10]. Of the genes identified, some are specific to CD 
or UC, whereas some are shared between CD and UC (Figure 1.2) [10,28,31]. 
Interestingly, many of the genes associated with IBD, such as NOD2, TLR, JAK2 and 
STAT3 play a role in the innate immune response [10,31]. 
Dysregulation of chemokines and chemokine receptors are thought to be particularly 
significant in the altered mucosal immune responses in IBD. Researchers have identified 
chemokine and chemokine receptors as potential targets for therapy in human diseases 
[33,34]. The C-C chemokine receptor type 6 (CCR6) gene has recently been identified to 
be associated with Crohn’s disease [35]. 
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Figure 1.2: Unique and shared susceptibility gene loci in CD and ulcerative colitis.   
The loci, depicted by lead gene name attaining genome-wide significance, are shown for CD in 
red, UC in blue, and IBD in black. Reproduced from C.W. Lees et al. [35]. 
 
1.4 Intestinal immune system 
 
The intestinal epithelium consists of a single layer of epithelial cells and is interconnected 
by close-knit junctions covered by mucus, providing a mucosal barrier that prevents the 
entry of luminal toxins, microorganisms and foreign antigens [36]. The intestinal 
epithelium encounters up to 10
14
 of luminal microbes 
 
[37], comprising over 500 different 
species, on a regular basis [38]. It has selective permeability and allows passage of dietary 
nutrients, water and electrolytes to enter into the circulation from the intestinal lumen 
[36,39,40]. The intestinal mucosa is rich in tissue macrophages and lymphocytes [41]. 
The prevention of bacterial penetration, invasion and systemic spread is essential in 
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maintaining immune homeostasis [36]. Immunological tolerance towards commensal 
microbes and the effective responses mounted to an external pathogen needs to be well 
balanced for both preventions of disease and maintenance of homeostasis [42]. Mucin, a 
protein produced by intestinal goblet cells, forms an integral part of the mucus layer 
covering the intestinal epithelium along with antibodies, defensins and lysozymes [43-
45]. The outer loose mucus layer serves as the first physical and chemical barrier to the 
luminal microbes, while the inner mucus layer is essentially sterile and contains a number 
of antimicrobial peptides [41,46]. A range of antimicrobial peptides is produced by 
Paneth cells, which are granulated cells located at the base of small intestinal crypts. 
Paneth cells prevent microbial invasion in the small intestine by secreting α-defensins, 
lysozymes and secretory phospholipase A2 [47]. The epithelial cells are involved in the 
host’s defence mechanism and they internalise the incoming gram-negative bacteria 
through phagocytosis. Goblet cells are also involved in delivering luminal antigens to the 
immature dendritic cells for antigen sampling [45]. 
Microbial cell wall components such as lipopolysaccharide (LPS) can stimulate 
enterocytes, provoking an innate immune response with an increased production of 
interleukin 8 (IL-8) via activation of the transcription factor nuclear factor kappa B (NF-
κB) [48]. The microfold cell (M cell) is a unique cell type which is present in the follicle-
associated epithelium (FAE) covering the Peyer’s patches. These, along with intestinal 
dendritic cells, are involved in luminal antigen sampling [49]. Neutra et al. [50] suggested 
that the uptake of immune complexes by M cells may regulate mucosal immune 
responses, but the exact significance of the interaction between the M cells and the 
intestinal antibodies remains unknown.  
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1.4.1 T cells 
 
The dendritic cells mature as they migrate from intestinal peripheral or inflamed tissue 
and transfer antigens to the mesenteric lymph node where naïve T cells undergo 
differentiation after an antigen encounter [51]. The differentiation of T cells often 
depends on the cytokine environment and an intricate association between cells of innate 
and adaptive immune responses [52,53]. CD4
+
 T cells differentiate into T regulatory 
cells, Th1, Th2 and Th17. Both Th1 and Th2 produce some cytokines such as interferon-γ 
(IFN-γ), lymphotoxin-α (LTα), interleukin-4 (IL-4), IL-5 and IL-13, in response to 
stimuli by pathogens [54].  
Until recently, Th1 cells were shown to be involved in mediating a number of 
autoimmune conditions [54,55]. T helper lymphocytes, requiring IL-23 for differentiation 
and producing IL-17, IL-17F, IL-21 and IL-22, have been identified as a new subset of T 
cells known as Th17 effector cells [54]. Th17 effector subpopulations have been observed 
to have more plasticity in phenotype [52]. Th17 cells mediate dysregulated intestinal 
inflammation leading to the progression of the disease but the mechanics are highly 
debated and remain unresolved [56]. T regulatory cells are stimulated by IL-10 secretion 
of the dendritic cells [57-61]. CD4
+
 T cells expressing forkhead box P3 (FOXP3) promote 
tolerance to the intestinal flora, and IL-10 producing cells comprise a major portion of 
intestinal regulatory cells [61].    
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Antigenic peptides are presented by major histocompatibility complex (MHC) molecules 
to T cells which then initiate a cascade of events to destruct pathogens [62]. The intestinal 
tissue microenvironment and the local cytokine environment enhance the T cell receptor 
(TCR) activated CD4
+
 T cell differentiation into IL-10 and TGF-β producing cells [63]. T 
regulatory cells assist in maintaining immunological homeostasis in the gut by avoiding 
inappropriate immune responses [61]. Effective communication between the intestinal 
epithelial barrier and innate and adaptive immune cells is vital in maintaining intestinal 
homeostasis and also in preventing any disease process (Figure 1.3) [64]. Impaired innate 
and adaptive immune response involving Th17/Th1 inflammatory response and increased 
inflammatory cytokine production is thought to initiate IBD [65]. 
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Figure 1.3: Pathophysiology of IBD.  
(a) The intestinal immune system encounters numerous antigens and distinguishes between 
invasive organisms, dietary antigens, proteins, and commensal bacteria. The intestinal 
homeostasis depends on the dynamic crosstalk between the microbiota, the intestinal epithelial 
cells, and the resident immune cells.  
(b) Various regulatory mechanisms are involved in maintaining intestinal homeostasis. The 
disturbance of this balance triggers the chronic inflammatory process found in inflammatory 
bowel disease. In early inflammation, foreign antigens activate the various innate immune cells 
located in the intestine, including natural killer cells, mast cells, neutrophils, macrophages, and 
dendritic cells.  
(c) Maintenance of the inflammatory environment promotes the activation of the adaptive 
immune response. Aberrantly activated effector T helper (Th) cells synthesise and release 
different inflammatory mediators which turn into a vicious circle of inflammation leading to 
chronic tissue injury and epithelial damage.  
Reproduced from J. Galvez [66]. 
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1.5 Chemokines 
 
Chemokines are a large family of small (8-12kDa) globular proteins which mediate the 
chemotaxis and chemo-attraction vital to the effective functioning of macrophages, 
lymphocytes, neutrophils and monocytes [67,68]. Chemokine activity is mediated by 
interaction with chemokine receptors belonging to a superfamily of seven-
transmembrane-domain G-protein-coupled receptors [67]. Between 40 and 50 human 
chemokines have been identified so far, with approximately 20 human chemokine 
receptors identified, suggesting that receptors have multiple binding partners [68,69].  
Chemokines are classified into two broad groups based on their functions, homeostatic 
and inflammatory [25,67]. Homeostatic chemokines are constitutively expressed in a 
particular tissue environment and are involved in physiological trafficking and cell 
migration [70]. Inflammatory chemokines are up-regulated and are involved in recruiting 
the lymphocytes, neutrophils and macrophages during an inflammatory response [67]. 
Chemokines are involved as pro-inflammatory agents and enhance the recruitment of 
lymphocytes and different types of leukocytes to the site of inflammation by binding to 
their G-protein coupled receptors on the surface of immune cells [71]. Hence, chemokines 
are powerful pro-inflammatory chemotactic cytokines, requiring stringent control over 
their regulatory mechanism [72]. 
 Dysregulation of chemokines is strongly implicated in many acute and chronic 
inflammatory diseases such as respiratory diseases, arthritis and atherosclerosis [73]. At 
the focal site of inflammation, inflammatory chemokines are released, facilitating the 
ongoing migration of effector cells in a chronic inflammatory environment [74]. 
Chemokine inhibition results in an anti-inflammatory environment, whereas promoting 
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their activity may lead to wound-healing process. Chemokines are therefore attractive 
potential targets for the development of new therapeutic agents for chronic inflammatory 
disease [75,76].  
Chemokines are classified based on the different amino acid sequence around the first 
two N-terminal cysteine residues [67] and divided into distinct subclasses CXC, CC, 
CX3C and XC, and an addition of R for the receptor, followed by a number indicating the 
order of discovery [69,77,78]. Chemokines have three β- pleated sheets and a carbon 
terminal α-helix with disulphide bonds connecting cysteine residues [79]. Chemokines 
consist of structurally related secreted proteins of 67–127 amino acids in length [78] and 
they exist as a monomer, dimer or tetramer, the functional form being a monomer. The 
amino terminus NH2 is the most critical binding and activation site for the receptor-ligand 
(Figure 1.4), and the secondary binding site is present in the flexible loop region that is 
followed by the second cysteine [74]. Chemokines preferentially bind to seven-
transmembrane G-protein coupled receptors which are found on T cells and B cells and 
also on other cells such as neurons and endothelial cells [68]. Many chemokines bind to 
multiple receptors (Figure 1.5), whereas some chemokines bind specifically to a single 
receptor [80].  
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Figure 1.4: Structure and functional regions of chemokine receptors. 
Structure of seven-transmembrane G-protein coupled receptors and binding sites of chemokine 
receptors for ligand binding, receptor activation and internalisation. Reproduced from G.E. White, 
A.J. Iqbal & D.R. Greaves [81]. 
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Table 1.1: Nomenclature of Chemokine receptors and ligands. 
Classification  Receptors Systematic 
names of 
Ligands 
Human Ligands Mouse Ligands Function 
C family XCR1 XCL1, 
XCL2 
Lymphotactin  
SCM-1β 
Lymphotactin 
Unknown 
Inflammatory 
CX3C family CX3CR1 CX3CL1 Fractalkine Fractalkine Inflammatory 
CC family CCR1 
 
CCL3 MIP-1α/LD78α MIP-1α Inflammatory 
CCL5 RANTES RANTES 
CCL 7 MCP-3 MARC 
CCL14 HCC-1 Unknown 
CCL15  HCC-2 Unknown 
CCL16  HCC-4 Unknown 
CCL23 MPIF-1 CCL6, C10 
CCR2 CCL2 MCP-1/MCAF JE Inflammatory 
CCL7 MCP-3 MARC 
CCL8  MCP-2 MCP-2 
CCL13  MCP-4 Unknown 
CCL16 HCC-4/LEC LCC-1 
CCR3 CCL5 RANTES RANTES Inflammatory 
CCL7 MCP-3 MARC 
CCL 8 MCP-2 MCP-2 
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CCL11 Eotaxin Eotaxin 
CCL13 MCP-4 Unknown 
CCL15 HCC-2/Lkn1/MIP-
1δ 
Unknown 
CCL16  HCC-4/LEC LCC-1 
CCL24  Eotaxin-2 Unknown 
CCL26   Eotaxin-3 Unknown 
CCL28 MEC ALP/CTACK 
CCR4 CCL17, 
CCL22 
TARC, MDC TARC,ABCD-1 Homeostatic 
CCR5 CCL3 MIP-1α/LD78α MIP-1α Inflammatory 
CCL4 MIP-1β MIP-1β 
CCL5 RANTES RANTES 
CCL8 MCP-2 MCP-2 
CCL11 Eotaxin Eotaxin 
CCL14 HCC-1 Unknown 
CCL16 HCC-4/LEC LCC-1 
CCR6 CCL20 MIP3-α MIP3-α Homeostatic 
CCR7 CCL19 
CCL21 
MIP-3β,ELC  
6Ckine, SLC 
MIP-3β 
6Ckine, SLC 
Homeostatic 
CCR8 CCL1 I-309 TCA-3, P500 Homeostatic 
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CCR9 CCL25 TECK MPIF-2 Homeostatic 
CCR10 CCL27, 
CCL28 
CTACK/ILC,  
MEC  
CTACK/ILC,  
ALP/CTACK 
Homeostatic 
CXC family CXCR1 CXCL6, 
CXCL 7, 
CXCL 8 
GCP-2,  
NAP-2,  
IL-8 
GCP-2/LIX, 
Unknown, 
Unknown 
Inflammatory 
CXCR2 CXCL1  
CXCL 2 
CXCL 3 
CXCL 5  
CXCL 6 
CXCL 7 
CXCL 8 
GROα/MGSAα 
GROβ/MGSAβ 
GROγ/MGSAγ  
ENA-78  
GCP-2 
NAP-2 
IL-8 
GRO/KC  
GRO/KC  
GRO/KC 
GCP-2/LIX 
GCP-2/LIX 
Unknown 
Unknown 
Inflammatory 
CXCR3-A CXCL9, 
CXCL 10, 
CXCL 11 
MIG,IP-10, 
I-TAC 
MIG,IP-10 
I-TAC 
Inflammatory 
CXCR3-B CXCL4, 9, 
10 &11 
PF4,MIG,IP-10, I-
TAC 
PF4, MIG,IP-10,I-
TAC 
Inflammatory 
CXCR4 CXCL12 SDF-1α/β SDF-1  Homeostatic 
CXCR5 CXCL13 BCA-1 BLC Homeostatic 
CXCR6 CXCL16 Unknown Unknown Inflammatory 
CXCR7 CXCL12 SDF-1α/β SDF-1 Inflammatory 
Adapted from [67,80,82-84]. 
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1.5.1 Chemokine ligand CCL20   
 
The chemokine receptor CCR6 uniquely interacts with the chemokine ligand CCL20 
(also known as Exodus-1), the macrophage inflammatory protein (MIP-3α), and the liver 
activation-regulated chemokine (LARC) [85-87]. Hieshima et al. [88] were the first to 
identify CCL20, a novel chemokine ligand expressed in the normal liver. The Ccl20 gene 
is located on chromosome 2q33-37 [88,89]. The chemokine CCL20 is largely expressed 
in the lung, liver and appendix, and to a lesser extent in the thymus and intestine. It is also 
expressed in peripheral blood lymphocytes and is up-regulated during an inflammatory 
stimulus [85]. Furthermore, the expression of Ccl20 is also found in various types of 
epithelial cells such as pulmonary epithelial cells, keratinocytes and also in intestinal 
epithelial cells. Ccl20 reportedly is constitutively expressed by B cells, dendritic cells and 
neutrophils, and its expression can be stimulated using pro-inflammatory ligands [90]. 
Follicle-associated epithelial cells (FAE) covering the Peyer’s patches of the intestine and 
the isolated lymphoid follicles (ILFs) are involved in the synthesis of Ccl20 [25]. Ccl20 
was reported to be expressed mainly in Th17 cells and not expressed by either Treg cells 
or T helper subsets [91]. Up-regulation of Ccl20 expression in intestinal epithelial cells 
can be seen in response to induction by invasive or non-invasive flagellated bacteria, 
suggesting a mechanistic link between Ccl20 synthesis and TLR3 [90,92].  
Furthermore, pro-inflammatory cytokines such as IL-1α or tumour necrosis factor (TNF) 
produced during acute intestinal inflammation also stimulate and up-regulate Ccl20 
expression [93]. Brand et al. reported that in the skin fibroblasts of chronic obstructive 
pulmonary disorder (COPD) patients, the Ccl20 expression is driven by IL-1β and αvβ8-
mediated TGF-β activation [94,95]. The periportal expression of Ccl20 in the liver 
facilitates CCR6+ve cells being recruited to encounter incoming invading micro-
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organisms, however, the periportal site is also the primary entry for colorectal cancer cells 
[86,88,96]. The ubiquitous presence of Ccl20 in inflamed mucosal sites suggests its 
possible role in the initiation and recruitment of adaptive immune responses. 
1.5.2 Chemokine receptor CCR6  
 
Chemokine receptor 6, originally known as STRL22, was identified in 1997 by Liao et al. 
[97]. The CCR6 gene in humans is located on chromosome 6q27 and is expressed in the 
intestine by dendritic cells (DC), subsets of T cells (CD4
+
, CD8
+
), and in most B cells 
[67,98-100]. Furthermore, CCR6 is also expressed by central and effector memory T cells 
which are characterised by the expression of CCR7 [101,102]. Apart from the expression 
of CCR6 on Th17 cells, CCR6 recently was reported as being expressed by IL-22-
producing NK cells, IL-17 producing γ/δ T cells and a subpopulation of CD4+ FOXP3+ 
regulatory T (Treg) cells [103-106]. To date, CCR6 appears to be expressed 
predominantly in mucosal tissues of skin and intestine [107,108].  The CD4
+ T cells and 
dendritic cells migrate into the gut mucosal tissue in response to inflammation and their 
migration is thought to be mediated by CCR6 [98].  
Recent studies have identified CCR6 as a specific marker for Treg cells and Th17 cells 
[103,109]. Th17 cells are reported to be involved in mucosal immune responses elicited 
due to bacterial and fungal pathogens [107]. CCR6 is expressed by both Th17 and T 
regulatory cells, and recent studies suggest that both have opposing roles in autoimmune 
diseases [91]. Ccr6 is a susceptibility gene, strongly involved in Crohn’s disease 
[110,111]. An in vitro study of differentiated T effector and T helper subsets by 
Yamazaki et al., [91] showed mRNA and protein expression of Ccr6 as being very high 
in Th17 cells when compared with the small amounts of expression seen in Th1 and Th2 
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cells. Evidence of CCR6 expression in Treg cells, both in vivo and in vitro, was reported 
by Kleinewietfeld et al., which is consistent with the findings of Yamazaki et al. [91,103].  
 
1.5.3 CCR6-CCL20 axis 
 
The CCR6-CCL20 axis is an important factor in intestinal immunity. Ito et al. [75] 
describe the involvement of the CCR6-CCL20 axis during the normal development of 
innate immunity and immune homeostasis. In intestinal immune responses, especially in 
the innate immune response where CCR6-mediated signals are important, the CCR6-
CCL20 axis might have a very significant impact on tissue damage and injury [98]. It has 
been suggested that CCR6 is associated with the regulation of leucocyte migration 
followed by effector function of T cells, all of which are considered to be important 
factors in gut immunity [98,110]. Induction of CCL20 by bacterial lipopolysaccharide 
(LPS) endotoxin in response to infection occurring in intestinal epithelial cells has been 
demonstrated [112]. The CCR6-CCL20 axis also mediates the chemotaxis of dendritic 
cells and macrophages by facilitating their migration to the site of inflammation [98]. 
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Figure 1.5: Schematic representation of CCR6 role in intestinal inflammation. 
CCR6 is expressed in both T regulatory cells and Th17 cells thought to be the pivotal link 
between anti-inflammatory and pro-inflammatory cells. During inflammatory stimulus, the 
CCR6-CCL20 axis is critical in skewing towards either tolerance or inflammation. (Mø-
macrophages and DC- dendritic cells) 
 
Le Borgne et al. [113] demonstrated the significant involvement of CCR6-CCL20 in the 
migration of dendritic cells from the blood to the lamina propria of the intestine during 
the inflammatory process (Figure 1.6) [113]. Th17 cells and Treg cells are present in large 
numbers in the lamina propria during normal as well as inflammatory conditions, 
suggesting that the axis is critical for the outcome of intestinal pathology [114]. 
Maintaining the balance between inflammatory cells and T regulatory cells is vital for the 
outcome of intestinal pathologies [114]. The CCR6-CCL20 axis has been demonstrated to 
play an important role in many lung and gut disorders [98]. Furthermore, the CCR6-
CCL20 axis is of notable importance in colorectal cancer and in autoimmune diseases 
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[103,115]. The CCR6-CCL20 axis appears to hold promise as the new target for 
therapeutic interventions in many diseases, including IBD [114]. 
CCL20 was reported to be expressed only in Th17 cells and it was not expressed by either 
Treg cells or T helper subsets [91]. In intestinal immune responses, especially in the 
innate immune response where CCR6-mediated signals are important, it might have a 
very significant impact on tissue damage and injury. Frick et al. [96] emphasise the need 
for more functional studies to prove the role of the CCR6-CCL20 axis in tumour 
development. Recent reports from Uchida et al. [116] suggested that the CCR6-CCL20 
axis plays a significant role in ensuing pathological changes in paediatric ulcerative colitis 
patients when compared to the adult patients. Uchida et al. [116] demonstrated a 
significant increase in the production of Ccl20 by colonic epithelial cells and increased 
expression of Ccr6 in the infiltrating inflammatory cells of the mucosal layer. The 
statistically significant findings corresponded to the histological outcome, leading to an 
increase in the disease severity being observed in paediatric patients compared to adult 
patients.  
Studies using Ccr6
-/- 
mice suggest that the CCR6-CCL20 axis has an important role in the 
immune process leading to inflammatory bowel disease [87]. Wild-type Th17 cells or 
Ccr6
-/- 
T cells, when transferred into a Rag1ˉ/ˉ severe combined immune-deficient (SCID) 
mouse, resulted in severe intestinal inflammation [104,117]. Reduction in the population 
of Th17 and Treg cells was noted in this process [104,117]. According to these results, 
Lee et al. [117] suggest that the function of CCR6 is more important to Treg cells than 
Th17 cells. The relationship between CCL20 and its receptor CCR6 determines the 
balance between Treg and Th17. The outcome largely relies on the selective skewing of 
CCR6-CCL20 to establish whether the prominence of either Treg or Th17 is an essential 
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factor in the process of intestinal inflammation. The responses towards CCL20 by both 
Th17 and Treg cells which also express CCR6 leads to a feedback loop resulting in 
intestinal inflammation.  
                  
1.6 Mouse models of IBD 
 
Mouse models have been used in many areas of biomedical research since they bear a 
very close similarity physiologically to humans. Researchers use mouse models to get a 
better understanding of the disease process and to develop and trial new therapeutics 
[118,119] and, as such, they are regarded as a valuable tool in IBD [120]. Based on the 
development of colitis, mouse models can be broadly categorised as:  
1. Chemically induced colitis  
2. Adoptive T cell transfer induced colitis 
3. Genetically engineered models of colitis         
4. Spontaneous models of colitis 
1.6.1 Chemically-induced Colitis 
 
The commonly used chemicals to induce colitis are dextran sodium sulphate (DSS), a 
chemical colitogenic, oxazolone and 2, 4, 6-trinitrobenzene sulfonic acid (TNBS). The 
administration of chemicals such as DSS causes the animals to develop inflammation 
resembling human colitis [121-123]. DSS is the most widely used chemical to induce 
colitis in mouse models as it is easy to administer: it is dissolved in drinking water in 
single or multiple cycles and leads to acute or chronic colitis [124]. The cytotoxic effect 
of DSS is conferred onto the intestinal epithelial cells, efficiently breaching the barrier 
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function and exposing the luminal microbial flora of the bowel [124,125]. The colitis 
induced by oxazolone and DSS, when histologically analysed, seem to show close 
similarity to UC, whereas TNBS-induced colitis shows similarity to CD [126]. Induction 
of intestinal perforation causing the death of animals, diverse intestinal microflora, and 
optimisation of dosages owing to the genetic heterogeneity of mice are thought to be the 
disadvantages of the chemically induced mouse models [121].  
 
1.6.2 Adoptive T cell transfer induced colitis 
 
The adoptive transfer model provides extensive knowledge of the role of T cells, B cells 
and innate cells in various stages of inflammatory colitis in mice [127-129]. Transfer of 
CD45RB
high 
naïve T lymphocytes occurs into severe combined immune-deficient (SCID) 
or recombination activation gene 1 (Rag1
-/-
) immune-deficient recipients as these are 
devoid of T regulatory cells (Treg) cells. The colitis demonstrated in adoptive transfer 
mouse models closely mimics chronic inflammation as seen in human IBD patients. The 
severity of the inflammation varies, largely depending on the choice of the donor strain 
and the recipient strain [130,131]. As a result of the interaction between naïve donor T 
cells and the innate immune cells of the recipient, chronic inflammation ensues. 
Treatment with antibiotics and anti-inflammatory drugs ameliorates adoptive transfer 
colitis similar to IBD [130,132]. Lack of Treg cells in the adoptive transfer model leads to 
intolerance towards luminal microflora and an abnormal immune response is elicited. The 
altered immune response, one of the contributing factors for the onset of IBD, is well 
demonstrated by exhibiting poor immune homeostasis in adoptive transfer colitis. The 
disadvantages of using mouse models are that they are artificial and the unnaturally 
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created immune environment in immune-deficient mice is in contrast to the naturally 
occurring human IBD environment [130,132]. 
 
1.6.3 Genetically engineered mouse models of colitis 
 
Genetically engineered mouse models are the most widely used and around 74  
spontaneous mouse models of IBD are classified under this category [133]. These 
genetically engineered mouse models are recent advances and arise from interventions 
such as gene insertions/gene alterations or gene deletions in known loci of interest, 
resulting in alteration of the immune mechanism, and they are used to study adaptive and 
innate immune functions [134]. Cell-specific conditional knockout, conditional 
transgenic, knockin, conventional gene knockout, transgenic, conventional transgenic, 
mutation knockin, and N-ethyl-N-nitrosourea (ENU) mutagenesis are all among these 
[135,136]. 
 1.6.3.1   Ccr6
-/- 
mice 
 
Ccr6
-/-
 mice were developed by replacing the mouse Ccr6 gene by homologous 
recombination technique and targeted disruption of the gene [137]. Ccr6
-/- 
mouse models 
are used to understand the immune responses and the role of the chemokine axis CCR6-
CCL20 in the intestine [87]. CCR6 is found to be expressed selectively by the T cells, B 
cells and also in the subpopulations of dendritic cells of mice and humans [100,138]. The 
chemokine ligand CCL20 has its specific chemokine receptor CCR6 [86], only found to 
interact with mice and humans [87].  
Ccr6
-/- mice possess underdeveloped Peyer’s patches and, as a result, reduction of CCL20 
expression by FAE was reported along with a compromised development of isolated 
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lymphoid follicles having been noted in Ccr6
-/-
mice [25]. These mice show a decrease of 
CD11b⁺, CD11c⁺ myeloid dendritic cells in the subepithelial dome of Peyer’s patches. 
These are displaced into the inter-follicular region and may not exist in Peyer’s patches of 
Ccr6
-/- 
mice [137,139].  
 The Ccr6
-/- 
mice have an impaired humoral response to orally administered antigen and 
they also fail to respond to rotavirus, an enteric pathogen as demonstrated by Cook et 
al.[140]. The developmental defects of mucosal-inductive places in Ccr6
-/-
 mice are the 
reason behind decreased immunoglobulin A (IgA) production to orally administered 
antigens [25]. Ccr6
-/- 
mice are useful in studying the function of M cells, as the interaction 
of the chemokine axis CCR6-CCL20 is said to play an important role in M cell 
differentiation [141]. Studies using Ccr6
-/-
 mice also show an increase in TCRα/β and T 
cell subpopulations which indicates a possible role of this chemokine receptor in immune 
regulation [95].   
In contrast, the Ccr6
-/-
 mice confer normal systemic immune responses to subcutaneous 
antigens. Research suggested CCR6 to be a regulator of both humoral and lymphocyte 
homeostasis in the intestine [139]. Ccr6
-/- 
mice, when treated with DSS, developed less 
severe intestinal inflammation compared to wild-type mice [87]. Interestingly, when 
Ccr6
-/- 
mice were treated with TNBS they showed increased susceptibility to intestinal 
inflammation in otherwise genetically resistant strains [87,114,142].  
Studies using Ccr6
-/- 
mice suggest that the CCR6-CCL20 axis plays an important role in 
the immune process leading to inflammatory bowel disease [87]. Ccr6
-/- 
mice have an 
increased T cell subpopulation within the mucosal layer of the intestine [137,140], with 
CCR6 being expressed on the cell surface of Th17 cells [143]. Interestingly, not all mouse 
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Th17 cells expresses CCR6, unlike in humans where all Th17 cells are shown to express 
CCR6 [91].  
It was observed that the alterations of the gut leukocyte homeostasis and the cytokine 
environment might confer disrupting effects on the functionality of the immune system 
[87,140]. The developmental defect of mucosal-associated lymphoid tissues (MALT), 
which are inductive places in Ccr6
-/- 
mice, is due to decreased IgA production to orally 
administered antigens [25]. In contrast, the Ccr6
-/- 
mice display normal systemic immune 
responses to subcutaneous antigens [140]. Research suggested CCR6 to be a regulator of 
both humoral and lymphocyte homeostasis in the intestine [140]. Ccr6
-/- 
mice were used 
to demonstrate the role of CCR6 and its importance in many lung and gut disorders [98]. 
 
1.6.4 Spontaneous models of colitis 
 
1.6.4.1 Winnie mice 
 
In the field of IBD study, there are two valuable mouse models derived from ENU 
mutagenesis targeting the mucin 2 gene (Muc2), namely Winnie and Eeyore.  A point 
mutation in Muc2 causes misfolding of the mucin and initiates an unfolded-protein 
response (UPR), resulting in endoplasmic reticulum (ER) stress [43]. Initiation of chronic 
inflammation involving both innate and adaptive immunity is mediated by ER stress and 
leads to the development of severe colitis spontaneously in mice [132]. Winnie is one 
such mouse model which is proven to be a spontaneous model of intestinal inflammation 
[43]. One significant feature of this model is that Winnie mice have a primary epithelial 
defect but their underlying immune system is normal. The nature of the inflammatory 
response in Winnie mice has been extensively characterised (Figure 1.7) [43,144,145].  
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Figure 1.6: Schematic representation of the initiation of inflammation in Winnie 
mice.  
Reproduced from R.D. Eri et al. [145]. 
 
There is also an increase in gut permeability leading to the occurrence of severe colitis 
[43].  Increased production of inflammatory cytokines such as TNF-α, IL-1β and IFN-γ is 
seen in the distal colon explant cultures of Winnie mice. Also notably, an increased 
expression of Th17-related genes Il-17a, Il-17f, Tgf-β1 and Ccr6 in the intestinal mucosa, 
in particular, is seen in the distal colon of Winnie mice [43]. The Winnie mice display 
Th1, Th2 and dominant IL-23/Th17 immune responses similar to the human IBD patients. 
The pathogenic mechanisms in Winnie mice closely resemble ulcerative colitis, making 
these mice a valuable tool in IBD research [43,132]. 
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1.6.4.2 SAMP1/Yit mice 
 
The SAMP1/Yit mouse model was originally derived from the senescence-accelerated 
mouse P series (SAMP1) and was generated by Takeda et al. [146]. The SAMP1/Yit 
strain was utilised to study the genetics of ageing and accelerated senescence in a short-
lived strain. The SAMP1/Yit strain develops spontaneous inflammation with a primary 
epithelial cell defect and shows a close resemblance to Crohn’s disease pathology [147-
149]. The discontinuous pattern of inflammatory lesions was mainly observed in the 
terminal ileum and slightly less so in the caecum [149]. Interestingly, Matsumoto et al. 
[147] identified that under gnotobiotic conditions the SAMP1/Yit mouse strain was free 
from intestinal inflammation. 
1.6.4.3 TLR4 
-/-
 mice 
 
Toll-like receptor 4 is a protein encoded by the TLR4 gene. The TLR4
-/-
 mouse model has 
a point mutation in the coding region which provides insight into the role of these 
receptors in the pathogenesis of inflammatory bowel disease [150-152]. The TLR4 point 
mutation mouse model was first developed by Hoshino et al. [153]. A few TLR family 
members serve as a cell-surface receptor for lipopolysaccharide (LPS), the major cell-
wall component of Gram-negative bacteria [154].  
However, TLR4
-/-
 mice are unresponsive to LPS as TLR4 is integral to the LPS response, 
which assists in better understanding the innate immune responses to bacteria and their 
role in this model [154,155].  
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1.7 Therapeutic strategies for IBD 
 
Conventional therapies involve the use of anti-inflammatory drugs: aminosalicylates and 
steroids. Immunomodulators such as azathioprine, 6-mercaptopurine, methotrexate or 
cyclosporine are also being used in patients who are resistant to or dependant on steroids. 
Biological therapies have gained importance in IBD therapy and targeted therapies with 
anti-inflammatory cytokine-therapy such as an anti-TNF-α antibody, anti-IL-6R, and anti-
IL-12 or toxin-conjugated anti IL-7R, recombinant cytokines (IL-10 or IL-11) have been 
used for IBD therapy [18]. Current therapeutic advances in the clinical management of 
patients with IBD include biological agents such as TNF blockers, and inhibitors of 
cytokines such as IL-6, IL-6R, IL-12 and IL-23 blockers. Other therapeutic strategies 
such as modulators of cytokine signalling events including JAK inhibitors or SMAD7 
blockers and inhibitors of transcription factors GATA3 or RORγt are currently being 
investigated in clinical trials [156].  
The CCR6-CCL20 axis has been considered as a therapeutic target for autoimmune 
diseases such as psoriasis, dry eye disease (DED), rheumatoid arthritis (RA) and 
experimental autoimmune encephalomyelitis (EAE) [157-160]. Chemokine targeted 
therapies have lately gained interest as they are considered to be a specialised form of 
treatment. The targeting of chemokines is likely to be an alternative to existing 
conventional treatments and biological treatments such as the use of TNF blockers along 
with disease-modifying drugs which result in immunosuppression as one of the side-
effects among many others in some of the recipients [160]. 
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1.8 Summary 
 
As demonstrated by evidence from various research groups, the CCR6-CCL20 axis may 
be a pivotal link in the balance between the Th17 cells and T regulatory cells [161]. The 
specific role of this axis is unknown. In this study, the overall aim is to develop a CCR6-
deficient spontaneous mouse model and to understand the role of the CCR6-CCL20 axis 
in the intestinal inflammatory environment. The focus of this study is the assessment of 
the CCR6 role in Winnie colitis. Based on the experimental outcomes achieved in the 
new mouse model, further experiments involving IBD patients could be planned. If the 
pathogenic role of CCR6-CCL20 in Winnie colitis can be demonstrated, then future 
studies targeting the CCR6-CCL20 axis may be a novel approach to a plausible IBD 
treatment. 
Research involving the CCR6-CCL20 axis and its role in various autoimmune disorders is 
of particular interest to the global scientific community. The CCR6-CCL20 axis needs to 
be further investigated as a clear understanding of its role with regard to inflammatory 
bowel disease is essential. CCR6 appears to be a pivotal link between the anti-
inflammatory and pro-inflammatory cells, with the CCR6-CCL20 chemokine axis 
mediating the inflammatory pathway. The significance of this current study is to study the 
effects of CCR6 deficiency in a spontaneously occurring colitis mouse model. The 
highlight of our model is that it is a spontaneous occurring colitis due to an SNP, unlike 
the existing contrived IBD mouse models. CCR6 is suggested to be involved in both 
immune regulation and enhancement of inflammation due to its presence in both Treg 
cells and Th17 cells. The interaction between the chemokine receptor and ligand in 
events, activation and resolution of colitis require further definition to understand the 
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pathological skewing toward chronic inflammation. Identification of the CCR6 role in 
colitis would be a valuable biomarker and hence a potential therapeutic target for IBD. 
 
1.9 Hypothesis 
 
Genetic ablation of the Ccr6 gene exacerbates intestinal inflammation in a spontaneous 
colitis mouse model.     
 
1.10 Project Aims 
 
The overall aim of this study is to understand the functional role of CCR6 in colitis by 
developing a Winnie x Ccr6
-/- 
mouse model. 
1. Generation of Winnie x Ccr6
-/- 
mouse model. 
2. Assess the role of Ccr6 in intestinal inflammation using clinical and histopathological 
parameters in Winnie x Ccr6
-/- 
mice. 
3. Analysis of immunological, molecular and cytokine profile of Winnie x Ccr6
-/- 
mice. 
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Chapter 2 
Materials and Methods 
 
2.1 Experimental Mice 
 
The mice used for this research project were imported from Jackson Immuno Research 
Laboratories, Inc. PA, USA, and bred directly at the University of Tasmania Cambridge 
Farm facility, or sourced from Monash University, Victoria. The mice were rederived and 
bred at a specific pathogen-free facility at Cambridge Farm and then transported to the 
PC2 animal facility at the Menzies Institute for Medical Research, Hobart. Mice utilised 
for this project (Table 2.1) were all aged between 8–12 weeks. All animal procedures 
were approved by the Animal Ethics Committee of the University of Tasmania (Ethics 
no. A0013691), and were conducted in accordance with the Australian code for the care 
and use of animals for scientific purposes 8th edition (2013), set out by the National 
Health and Medical Research Council. 
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Table 2.1:  Experimental strains of mice 
Animal strain Age Sex Phenotype 
C57BL/6J 
(JAX
® 
stock no-000664)  
Wild-type /B6 
8–12 weeks F/M Wild type 
Ccr6
-/-
 
(JAX® stock no-005793)  
B6.129P2-Ccr6
tm1Dgen
/J 
8–12 weeks F/M Targeted knockout 
Winnie 8–12 weeks  F/M Muc2 mutation 
Winnie x Ccr6
-/-
 8–12 weeks  F/M Muc2 mutant and targeted 
knockout for CCR6 
 
    2.2 Clinical assessment 
 
Mice were weighed prior to euthanasia and culled using a CO2 chamber. Under sterile 
conditions, spleen and mesenteric lymph nodes were harvested.  The harvested lymph 
nodes and spleen were stored in RPMI 1640 culture medium (Life Technologies Pty 
Ltd, Victoria, Australia) supplemented with 10% v/v foetal calf serum (FCS) (Life 
Technologies, Victoria, Australia), penicillin (100 mU/L) and streptomycin (100 
mg/L) (Sigma-Aldrich Pty Ltd, NSW, Australia). The large intestine was retrieved 
and was placed on a non-absorbent surface. The length of the colon was measured 
from the caeco-colic junction to the rectum and was recorded. The whole colon was 
cut open in a longitudinal axis; faecal contents were removed and weighed. The 
opened colon was then bisected longitudinally. One half, containing the proximal and 
distal colon, was carefully rolled into a Swiss roll and preserved in 10% formalin until 
further processing. The other half of the proximal and distal colon sections were used 
for explant cultures. The remaining part of the colon sections was cut into pieces and 
snap-frozen at ̶ 80 ̊C for RNA extraction.  
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                              Tissue Harvest from Mice 
   Mice weighed (body weight)   
  
         Mice culled      
 
  Tissue harvest           Mesenteric lymph nodes         RPMI on ice            
            
                                          T cell activation 
Colon length 
     
    Colon cut open 
 
    Wet colon weight 
 
   Colon cut into two equal halves 
    
One half  Other half snap-freeze/media in ice respectively 
  Swiss roll                      PC 
         - RNA,  
         - explant culture (weighed tissue)         
                                                                                
         - RNA,  
10% Formalin        -explant culture (weighed tissue) 
                DC 
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2.3 Genotyping 
 
The DNeasy Blood & Tissue Kit (Qiagen Pty Ltd, Victoria, Australia) was used for 
genomic DNA (gDNA) extraction. Mouse-ear clips were lysed overnight using the 
supplied proteinase K and lysis buffer. Lysis was performed at 56°C with constant 
agitation at 500rpm using an Eppendorf ThermoMixer® C. Lysed samples were then 
transferred to spin columns and processed according to the manufacturer’s protocol and 
genomic DNA eluted (200μL). DNA concentration (10ng/mL) was determined using 
Qubit®2.0 Fluorometer (Life Technologies, Victoria, Australia).  
 2.3.1 Winnie SNP genotyping assay  
 
The presence of the Winnie Muc2 mutation was confirmed using a custom-designed 
Winnie SNP PCR assay (Life Technologies, Assay ID: AHCSX8U, Catalogue No: 
4332077, Size: 1500rxn, 40x) diluted in 1 x TE buffer to 20x working stock. TaqMan 
genotyping master mix (Catalogue no: 4371355, 10mL and Catalogue no: 4371353, 1mL) 
or TaqMan® GTXpress™ Master Mix (Catalogue No: 4401892, 10mL) was used for the 
SNP assay. A volume of 5µl of 2 x Master mix, 0.5µl of 20x SNP, 3.5µl molecular grade 
H2O, and 1µl of genomic DNA (10ng/µl) was used in a 10µl reaction volume for the SNP 
assay. 
2.3.2 Ccr6 genotyping polymerase chain reaction 
 
Deletion of the Ccr6 gene was confirmed using the CCR6 primers (20µM) (Table 2.2) 
purchased from GeneWorks Pty Ltd, Adelaide, Australia. HotStar Taq Master Mix Kit 
(Catalogue no: 203445, Qiagen Pty Ltd, Victoria, Australia) was used with 2µl of 
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genomic DNA in a reaction volume of 20µl and thermal cycling performed using a PTC-
200 Thermal Cycler (MJ Research). 
 
Table 2.2: CCR6 genotyping primer list 
Primer Sequence Length Tm 
 
CCR6 
5' 
ORF 
 
 
5'--‐GTCATCACCACCATAATGTTG 
 
 
 
 
21 
 
 
 
 
55 
 
 
 
CCR6 
5' 
UTR 
 
 
 
5'--‐TCTGCACTAGTGAGAGTGTG 
 
 
20 
 
 
55 
 
 
CCR6 
neo 
rev 
 
 
5'--‐GAACGAGATCAGCAGCCTCTGTTCC 
 
 
25 
 
 
55 
 
 
2.3.3 CCR6 gel electrophoresis  
 
The PCR products were analysed on 2% w/v agarose gel prepared in 1X TBE buffer. A 
volume of 3µL of 10,000X SYBR Safe™ DNA Gel Stain (Invitrogen Technologies) was 
added to the agarose gel and mixed well. A volume of 5µl of DNA Easy ladder I (Bioline, 
NSW, Australia, Catalogue No: BIO-33046) was dispensed into the ladder well and 4µl 
of PCR product and 1µl of DNA loading dye and appropriate control samples and test 
samples. The gel was run at 150mV 200mA for 30 minutes and images were viewed 
using Easy Image analyser. 
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2.4 Flow cytometry 
 
Mouse spleen and mesenteric lymph nodes (MLNs) were harvested. Both spleen and 
lymph nodes were crushed using the frosted ends of glass slides. A homogenous 
suspension was prepared using FACS Buffer (Table 2.4). Cells were collected after 
centrifuging at 1500rpm for 5 minutes at 4°C in Allegra® X15R  (Beckman Coulter, 
U.S.A.). The red blood cells (RBCs) were removed by resuspending the spleen samples in 
10mL of RBC Lysis Buffer and incubating at 37°C for 10 minutes. RBC free samples 
were then washed in FACS Buffer. Around 2 x 10
6
 cells were stained with 50μL of 
antibodies for 25 minutes on ice. Samples were then washed in 2mL of FACS Buffer as 
per the above centrifuge settings. Where purified antibodies were used, samples were 
blocked with 10% rat serum (Sigma-Aldrich®, Catalogue No: R9759) to prevent non-
specific background interference.  
For intracellular staining, the FOXP3 Fix/Perm Buffer kit was used as per the 
manufacturer’s instructions (BioLegend®, Cat no: 421403). Secondary antibodies are 
listed in Table 2.3. Cells were stained with T cell and B cell markers (Table 2.3) to detect 
the presence of respective population. Prior to data acquisition, samples were filtered 
using 48μm nylon meshes (Sefar, 03-50/31). Flow cytometric data were acquired using 
CyAn™ ADP Flow Cytometer (Beckman Coulter, USA) and analysed with Flow Jo 
version 10 (Tree Star Inc., U.S.A.) for Windows. 
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Table 2.3: List of flow cytometry antibodies used 
 
Antibody 
 
Manufacturer Dilution Catalogue 
number 
  
 CCR6 PE 
  
(Clone 29-247) 
 
BioLegend® 
 
 
 
 
1:100 
 
 
 
 
129-804 
 
Goatα-Rat IgG Alexa 
Fluor® 488  
  
(Secondary antibody) 
 
 
JacksonImmunoResearch 
Laboratories,Inc. 
 
1:200 
 
A-11006 
 
 
IL-17 Alexa Fluor 488 
 
(Clone: TC11-18H10) 
 
Intracellular 
 
 
BD Biosciences 
 
1:100 
 
17-5773-82 
 
 
FOXP3 APC 
 
(Clone: FJK-16s)  
 
Intracellular 
 
 
eBioscience 
 
1:200 
 
552094 
 
B220 (CD45 R)  
APC Cy
TM 
7 
 
(Clone: RA3-6B2) 
 
 
BD Biosciences 
 
1:200 
 
HM3628 
 
TCRαβ PB  
 
(Clone: H57-597) 
 
 
Life Technologies™ 
 
1:200 
 
H57-597 
 
 
CD4 PerCP-Cy™5.5  
 
(Clone RM4-5) 
 
 
BD Biosciences 
 
1:400 
 
550954 
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Table 2.4:  Buffers used in flow cytometry assays 
 
 
 
FACS Buffer 
 
100 mL 10x PBS 
1g BSA  
2 mL 10% Sodium Azide  
(Sigma-Aldrich®, S2002) 
H2O to 1 L 
 
 
RBC Lysis Buffer 
  
4.55g NH4Cl (Sigma-Aldrich®: A0171) 
10mL 1M HEPES (Sigma-Aldrich®, 
H3375) 
4.55g NH4Cl (Sigma-Aldrich®: A0171) 
10mL 1M HEPES 
(Sigma-Aldrich®,H3375) 
H2O to 500 mL 
 
2.5 Real-time polymerase chain reaction (qPCR) 
 
Colon tissues were homogenised on ice using disposable Omni Tip™ Plastic Generator 
Probes. RNA was extracted using Qiagen RNeasy mini kit (50) (Catalogue No: 74104), 
and an on-column DNase digestion was performed using RNase-Free DNase Set (Qiagen; 
Catalogue no: 79254) following the manufacturer’s protocol and eluted using 20μl of 
RNA. The purity of eluted RNA was assessed using the ratio of absorbance at 
260nm/280nm determined with an Eppendorf BioPhotometer (Eppendorf); samples above 
1.8–2 were utilised for qPCR. A 2x TaqMan® Fast Advanced Master Mix (Catalogue 
No: 4444557), 2µl of the template was used in a reaction volume of 20µl (25ng per 
reaction). qPCR was performed on StepOnePlus
TM
, StepOne Analysis software (version 
2.2.3, Applied Biosystems). TaqMan primers (Table 2.5) were used in a reaction volume 
of 20μl (25ng per reaction). The PCR plate was run (Table 2.6) on Applied Biosystems 
StepOnePlus™ Real-Time PCR Systems (version 2.2.3).  All samples were normalised to 
the control tissue sample and analysed using the 2
-ΔΔCT
 method [162]. 
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Table 2.5: List of TaqMan qPCR Primers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers ID Reference sequence 
Il-10 Mm00439614_m1 NM_010548.2 
Il-6 Mm00446190_m1 NM_031168.1 
Il-22 Mm0044241_m1 NM_020525.4 
Il-1β Mm00434228_m1 NM_008361.3 
Foxp3 Mm00475162_m1 NM_054039.2 
Tgf-β1 Mm01178820_m1 NM_011577.1 
Il-23a Mm01160011_g1 NM_031252.2 
Eef2 Mm01171434_g1 NM_007907.2 
Ccr6 Mm99999114_s1 NM_009835.4 
Ccl20 Mm01268754_m1 NM_016960.2 
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Table 2.6: Thermal cycling conditions for real-time PCR 
 
Applied 
Biosystems 
Real-Time 
PCR System 
Thermal cycling profile 
Parameter Polymerase 
activation 
     PCR 
(40 cycles) 
Hold Denature Anneal/Extend 
 
Temp. (
 ̊ 
C) 
 
95 
 
95 
 
60 
 
StepOnePlus
TM
system 
 
Time(mm:ss) 
 
00:20 
 
00.01 
 
00:20 
 
2.6 Explant culture 
 
Medium for culturing colonic explants was prepared using 500µL of complete RPMI 
1640 (Gibco 
TM
, In Vitro Technologies Australia Pty Ltd) supplemented with 10% v/v 
foetal calf serum (FCS; Gibco, Life Technologies, Australia Pty Ltd), penicillin (100 
mU/L) and streptomycin (100 mg/L) (Sigma-Aldrich Pty Ltd, NSW, Australia) was 
dispensed in a 24-well culture plate and kept on ice. Once the tissues were harvested they 
were weighed and then cultured for 24 hours by incubating at 37 ̊C with 5% CO2. After 
the incubation period the supernatants were collected from the culture plate and stored in 
-80̊ C until further analysis.  
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2.7 T cell stimulation assay 
 
2.7.1 Antibody coating 
 
Antibody coating for the assay plates was prepared according to the manufacturer’s 
protocol, a 5-10 µg/mL solution of anti-CD3e (Clone: 145-2C11, Catalogue No: 14-0031-
82, Size 100µg) in sterile PBS, and the assay was performed in duplicates. A volume of 
50µL of anti-CD3e antibody solution was dispensed to the experimental wells in the 96-
well assay plate. For the control unstimulated wells, 50 µL of sterile phosphate buffered 
saline (PBS) was added and the plate covered tightly with Parafilm
TM
 to avoid sample 
evaporation and kept at 4°C overnight. Prior to the addition of cells, 50µL anti-CD3e 
antibody solutions were pipetted out of each well on the 96-well plate. 
2.7.2 Enumeration of cells 
 
MLNs were crushed by the frosted ends of glass slides, and the resulting cell suspension 
filtered using a 5ml round-bottom polystyrene test tube with cell strainer cap (12 x 75 
mm, Catalogue No: FAL352235). Cell suspension was prepared and resuspended at a 
concentration of 1-2 x 10
6
/mL in complete RPMI  1640 (Gibco
TM
, Invitro Technologies 
Australia Pty Ltd) supplemented with 10% v/v  foetal calf serum (Gibco, Life 
Technologies, Australia Pty Ltd), penicillin (100 mU/L) and streptomycin (100 mg/L) 
(Sigma-Aldrich Pty Ltd, NSW, Australia). The culture plate wells were rinsed with 200µl 
of phosphate buffer saline (PBS) before the addition of cells. Anti-mouse CD28 (Clone 
37.51 grade, Catalogue No: 16-0281) was added to each well along with cell suspension 
in duplicates at a concentration of 2µg/mL (200µl/well), incubated at 37°C with 5% CO2. 
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Cells were harvested after 24 hours and supernatants were collected after a spin at 200xg 
for 5 minutes. Supernatants were stored at -80 ̊C until used. 
 
2.8 Cytokine assay 
 
The explant supernatants and T cell supernatants were analysed using a custom-made 
Milliplex Mouse TH17 Magnetic Bead kit of analytes (IL-10, IL-17A, IFN-γ, IL-1β, 
CCL20 & IL-23). The samples were centrifuged (Heraeus Biofuge Stratos) at 4°C at 
10,000xg for 15 minutes. The assay was performed according to the manufacturer’s 
protocol on a Bio-plex 200 System (Bio-Rad Laboratories, Inc., Hercules, CA). A volume 
of 25µl of the undiluted sample was added to each well of the assay plate. The 
fluorescence intensity (FI) for each sample was acquired and analysed with Bioplex 
Manager 6.0. The explant colon tissue sample supernatants were assessed for cytokine 
levels. Cytokine levels in the supernatant were normalised to tissue weight to obtain 
pg/ml of cytokines/1 gm of tissue.  
 
2.9 Histopathology  
 
Colon tissues were Swiss-rolled, fixed overnight with 10% formalin and embedded in 
paraffin. Tissue sections were cut to an approximately 3–5µm thickness by a rotary 
microtome and were stained with Gill’s haematoxylin and eosin (H&E). The H&E 
stained sections were imaged using an Olympus DP72 microscope. Dr Ruchira Fernando, 
the histopathologist involved in our study, modified the grading for colitis (Table 2.7) and 
scored the H&E tissue sections from all animals in a blinded manner. Cell counting was 
performed manually in 10 random microscopic fields at magnifications of 100x and 400x.  
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2.10 Data analysis 
 
The data analysis was conducted by using Graph Pad Prism version 5.01 (Graph Pad 
Software Inc., U.S.A.). All data were expressed as a mean ± standard error of the mean 
(SEM). One-way ANOVA (non-parametric) was used and the comparisons between 
groups were analysed using Dunn’s multiple comparison tests or Tukey’s multiple 
comparison tests. A resulting p-value of ≤ 0.05 was considered significant. 
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Table 2.7 Scoring sheet for H&E sections 
           PC              MC          DC 
1.Distribution of inflammation    
0=none    
1= focal    
2=multifocal    
2.Depth of Inflammation    
1=Mucosal    
2=Submucosal    
3=Transmural    
3.Lamina propria neutrophils    
0= none    
1= 1-10     
2= 11-20     
3= > 20    
4.Cryptitis    
0= no cryptitis    
1= cryptitis    
5.Crypt abscess    
0= none    
1=1-5    
2=6-10    
3=>10    
6.Goblet cell loss      
0= normal <10% loss     
1= 10-25%    
2= 25-50%    
3= >50%    
Crypt architecture    
0= normal    
1= mildly irregular    
2= moderate    
3= severe    
Crypt shortening    
0=No damage    
1=25% shortening (150-200µm)    
2=50% shortening(200-250 µm)    
3=75% shortening(250-300 µm)    
4=100% shortening (>300 µm)    
Ulceration    
0= None    
1= Superficial    
2=Deep    
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Chapter 3 
   Generation of Winnie x Ccr6
-/-
 mice 
 
 
3.1. Introduction 
 
Inflammatory bowel disease (IBD), a chronic intestinal inflammation, is reportedly 
developed by modulations in the intestinal immune responses which are determined by a 
complex interaction between environmental, genetic and microbial factors [163]. Animal 
models are used to mimic IBD in order to better understand the disease mechanisms and 
attempt to describe its aetiology. Recent advances in this field of research have been 
brought about by the use of animal models in which inflammation is developed by 
chemical induction or by genetic alterations [121,164]. Chemicals such as DSS, TNBS, 
and oxazolone are used to induce intestinal inflammation initiated by mucosal damage 
leading to either acute inflammation or chronic inflammation. There are a number of 
disadvantages associated with the use of chemicals, such as optimising dosages and 
differences in microflora, all leading to substantial variability in these factors [121].  
Genetic alterations are the alternative approach to chemically induced models of IBD as 
they assist in the development of chronic inflammation. The provision for genetic 
diversity and manipulations within the mouse genome facilitates applications critical for 
defining a gene function, gene mutation and/or gene inactivation in vivo [165,166]. Gene 
targeting was implemented to develop knockout mouse models, wherein thousands of 
genes have been knocked out in mice [165,167-169] Using modern techniques for gene 
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targeting or trapping, a knockout model for each mouse gene is ongoing globally [169]. 
Inactive genes or gene mutations are many a time responsible for human diseases. 
Genetic mutations are often demonstrated or reproduced using a mouse for studying 
diseases.  
Apart from being a good physiological analogue to humans, the size, lifespan and prolific 
nature of mice render them a valuable research tool [165]. Knockout mice proved to be a 
useful resource when studying a gene’s role in a specific gene deletion model. The 
phenotype of a knockout mouse gives an insight into the functions of the gene in vivo. 
Knockout models are imperative in identifying strategies to develop therapies for treating 
diseases [170]. Around 60 mouse models have been developed to date and are used to 
study IBD pathogenesis [119].  
One such mouse model, Winnie, known to closely mimic human ulcerative colitis, was 
produced using random ENU mutagenesis reported by Heazlewood et al. (2008). Mucin-2 
is a major component of the intestinal barrier, produced by goblet cells.  Mice develop 
spontaneous colitis by a single missense mutation in the Muc2 gene of the mucin protein 
leading to the misfolding of mucin, causing ER stress. The homozygous Win/Win 
phenotype displays a spontaneous colitis phenotype similar to ulcerative colitis in IBD 
patients with a Th17-dominated immune response [43].   
Genome-wide association studies reported that the CCR6 gene is one among the 30 
genomic loci implicated in IBD. CCR6 is a β-chemokine–specific receptor for CCL20 
(MIP-3α/LARC/Exodus) in both humans and mice. The CCR6-CCL20 chemokine axis 
reportedly plays a major role in many diseases such as rheumatoid arthritis, EAE, and 
many other immune-mediated diseases, including IBD. CCR6 is the sole receptor for 
CCL20 and the function of this axis during inflammation remains unclear. Using gene 
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targeting techniques, Ccr6
-/-
 mice were generated in order to study this issue [137,171]. 
Ccr6
-/-
 mice displayed reduced numbers of M cells and smaller Peyer’s patches, resulting 
in a reduction in the number of domes [49,172]. CCR6 is involved in the differentiation 
of B cells and Th17 lymphocytes [32]. Both Th17 and Treg cells express CCR6. Research 
studies suggest that the dynamic balance elicited by the CCR6-CCL20 axis between pro-
inflammatory Th17 cells and anti-inflammatory Treg cells either determines the 
development of inflammation or maintains a homeostatic environment. Studies using 
Ccr6
-/-
 mice suggest that the absence of the Ccr6 gene affects the Treg subset population 
more than the Th17 subset population [32]. Hence the focus of this study was to utilise 
and Ccr6
-/- 
mice
 
to develop a mouse model in order to study colitis and the changes 
associated with the absence of Ccr6.   
3.2. Aims /hypothesis 
 
The initial aim of this study was to generate and identify Winnie x Ccr6
-/- 
mouse model 
by crossbreeding and backcrossing Winnie and Ccr6
-/- 
mice. The hypothesis was that the 
Winnie and Ccr6
-/- 
mice when crossed would inherit the mutations from both genotypes.  
3.3. Results 
 
3.3.1 Generation of Winnie x Ccr6
-/- 
mice 
 
Based on the Mendelian pattern of inheritance, the strains of Winnie and Ccr6
-/- 
were set 
up to breed mice for this study. Winnie mice were imported to our breeding facility where 
they were rederived to produce specified pathogen-free (SPF) mice for breeding purposes. 
In our animal facility, the rederivation process is a standard procedure used to obtain SPF 
mice. A breeding plan was sketched to generate Winnie x Ccr6
-/- 
mice, and the 
heterozygous strains of Winnie (Win/WT) mice were rederived by crossing with WT 
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strain (Figure 3.1). This initial step was expected to produce 50% Winnie and 50% WT. 
Subsequently, heterozygous Winnie (Win/WT) mice were crossed with heterozygous 
Winnie mice and were expected to produce 25% homozygous, 50% heterozygous and 
25% wild type. In our third step, Winnie homozygous mice were crossed with Ccr6 
homozygous mice, and all pups produced were Winnie heterozygous and Ccr6 
heterozygous. Subsequently, in our fourth step, heterozygous Winnie mice and 
heterozygous Ccr6
 
mice were backcrossed with Winnie heterozygous and heterozygous 
Ccr6
 
mice, resulting in the generation of the following 9 different genotypes (Table 3.1). 
Winnie homozygous x Ccr6
 
homozygous mice were generated. 
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Table 3.1 Percentages of genotypes obtained in the Winnie x Ccr6
-/-
generation. 
 
Stages                                                 Genotype 
 Heterozygous 
(Het) 
Homozygous 
(Hom) 
Wild-type 
(WT) 
Mixed Ratio 
1  50%  
Winnie 
50%  
WT 
 1:1 
2 
 
50%   
Winnie 
25%  
Winnie 
25%  
WT 
 1:2:1 
3 
 
50%  
Winnie Het; 
50% 
Ccr6 Het 
   1:1 
4 25%  
Winnie Het; 
Ccr6 Het 
6.25% 
Winnie 
Hom; 
Ccr6 Hom  
6.25% 
Winnie WT; 
Ccr6 WT 
12.5% 
Winnie WT; 
Ccr6 Het 
1:9 
 
12.5% 
Winnie Het; 
Ccr6 Hom 
 
12.5% 
Winnie Hom; 
Ccr6 Het 
 
12.5% 
Winnie Het; 
Ccr6 WT 
 
6.25% 
Winnie Hom; 
Ccr6 WT 
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3.3.2 Winnie x Ccr6
-/- 
genotyping 
 
Genotyping was performed for each batch of pups to determine the respective genotype. 
Appropriate genotyping assays were then performed and homozygous Winnie and 
homozygous Ccr6
 
mice were identified. The homozygous (Win/Win) Winnie mice were 
identified using TaqMan SNP assay. A custom-made SNP for Winnie mutant strain 
detection using TaqMan probes was designed for the Winnie genotyping assay by Life 
technologies where the reporter/quencher for Allele-1 was VIC/MGB-FAM, Allele 2- 
FAM/MGB-NFQ (Figures 3.2 & 3.3). In the process of identifying the mutant alleles for 
Winnie, the automated analysis in Step One Plus software was utilised. Optimisations of 
Winnie and Ccr6
-/- 
mice were performed until a working protocol was developed for our 
study. For Ccr6
 
genotyping, PCR was performed using the primers outlined in the 
‘Materials and Methods’ chapter of this thesis (Table 2.5). The products were run on an 
agarose gel to identify the homozygous Ccr6
 
genotype. A DNA easy ladder was used to 
assist in identifying the fragments, and the size of fragments was 250 base pairs (bp) for 
homozygous Ccr6
 
and 350 base pairs for WT (Figure 3.4). 
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Figure 3.2 Distribution of allelic discrimination plots of genotypes.  
Allelic discrimination plot of SNP assay shows clusters of blue dots which represent Allele 
2/Allele 2 (Win/Win) homozygous Winnie mutants. Allele 1/Allele 2 (Win/WT) heterozygous is 
represented as a green cluster of dots, and Allele 1/ Allele 1 wild-type (WT) is represented as red 
dots. No template control (NTC) is represented in black. The SNP assay was performed using 
neat samples and appropriate controls for each genotype. 
 
 
 
Winnie  
 
WT 
Heterozygous 
NTC 
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Figure 3.3 Homozygous Winnie allelic discrimination plots 
Allelic discrimination plot showing clusters of homozygous Winnie mice represented by blue 
dots. Heterozygous control represented by a green dot, WT control represented by a red dot and a 
no template control is shown in black. A complete population of homozygous Winnie (Win/Win) 
was identified.      
 
 
 
 
Winnie 
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Figure 3.4: Ccr6
-/- 
genotyping amplicons.  
Agarose gel electrophoresis was performed and the amplified fragments were visualised on 2% 
agarose gel using SYBR safe DNA gel stain. A DNA easy ladder was used, product size band-
100-2000 bp. The product size was 250 bp for homozygous Ccr6 and 350 bp for WT.  
 
3.4 Discussion 
 
Rederivation of the Winnie mouse strain was performed to achieve SPF mice for our 
breeding program. Rederivation is a standard laboratory practice performed to maintain 
the health status of animals in our animal facility. Imported mice are always subjected to 
the rederivation procedure when procured from vendors or from other research labs which 
differ in veterinary health surveillance systems. The rederivation process assists in 
achieving ‘cleaned’ or decontaminated laboratory animals, which do not contain certain 
pathogens or any transmissible zoonotic diseases, thereby preventing the disease from 
spreading into the new housing facility [173]. Embryos were harvested for the process of 
rederivation and surgically implanted into the surrogate mice. After the surrogate mice 
were screened negative for unacceptable pathogens, the pups were considered as 
pathogen-free and were subsequently used for breeding purposes [173]. 
A mutant mouse strain, Winnie, was chosen for this study as this particular mouse strain 
displays non-complementing missense mutation in the Muc2 mucin gene. The mutation 
resulted in the development of mild distal intestinal inflammation in the Winnie strain. 
  WT 
    Homozygous Ccr6 
 
DNA Easy Ladder 
Heterozygous 
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Colitis was seen to develop in Winnie mice as early as within 6 weeks. Winnie colitis 
reportedly displays a disease similar to the ulcerative colitis-like phenotype. Increased 
intestinal permeability in Winnie mice further resembles disease as in ulcerative colitis in 
humans [43]. The single nucleotide polymorphism (SNP) is an alteration from a cysteine 
to tyrosine in the N-terminal D3 domain of Muc2 of Winnie mice. The aberrant 
oligomerization of Muc2 resulted in ER stress and subsequently initiated UPR, eventually 
leading to spontaneously occurring colitis. Unlike other contrived models, Winnie mice 
develop spontaneous chronic colitis due to defective Muc2 biosynthesis, followed by 
inflammation and goblet cell dysfunction, and hence were chosen to be used in 
developing the Winnie x Ccr6
-/- 
model for this study. Ccr6
-/- 
mice reportedly have an 
altered intestinal immune system, underdeveloped Peyer’s patches and absence of 
isolated lymphoid follicles (ILF) [137,174]. In the intestinal mucosa, the Ccr6 gene was 
reportedly a major regulator of lymphocyte homeostasis and humoral immunity 
[137,140]. Varona et al. (2001) suggested that since CCR6 is involved in both 
homeostasis and inflammation, Ccr6
-/- 
mouse models are a useful tool for studying 
inflammatory diseases such as IBD and hence this model was chosen for this study.    
A breeding program (Figure 3.1) was created for the generation of Winnie x Ccr6
-/- 
mice, 
the rederivation process of Winnie mice with WT mice was performed and the embryos 
were aseptically transferred and surgically implanted into surrogate Swiss Webster mice. 
Winnie heterozygous (Win/WT) mice were then mated with Winnie heterozygous 
(Win/WT) mice which subsequently produced 50% homozygous and 50% heterozygous 
pups. In the next stage, homozygous Winnie mice were then crossed with Ccr6
 
heterozygous mice which resulted in heterozygous pups for both Winnie and Ccr6. 
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 Backcrossing of heterozygous Winnie mice and heterozygous Ccr6
 
with heterozygous 
Winnie and Ccr6 mice resulted in pups of 9 different genotypes (Table 3.1). The 
homozygous Winnie mice and Ccr6
 
homozygous mice were subsequently used to 
generate our Winnie homozygous x Ccr6 homozygous experimental mice.    
Genotyping was performed to identify the respective genotypes of the pups produced in 
each litter. An SNP assay for genotyping was performed as described previously, and the 
SNP assay detected the SNP in Winnie mice and identified the alleles for all respective 
genotypes and the Winnie mutant. The genotype of each mouse was identified by allelic 
discrimination plots (Figures 3.2 and 3.3) using an SNP assay for Winnie mice, and  
Ccr6
 -/- 
genotyping was performed by PCR and the resulting amplicons were identified by 
agarose gel electrophoresis (Figure 3.4) to confirm the Ccr6
 
gene deletion.  
Optimisation of the genotyping protocol for both Winnie and Ccr6
-/-
 was performed and 
appropriate protocols were subsequently utilised for identification of genotypes. Results 
of genotyping were analysed by using appropriate Step One software for Winnie mice 
and confirmed accordingly. The amplicons of Ccr6
-/-
 mice genotyping were run on an 
agarose gel, and a DNA ladder was used to identify the amplicons of WT/heterozygous/ 
homozygous Ccr6
 
mice, eventually
 
confirming their genotype according to the size of the 
amplicons. A ratio of 1:9 as per Mendelian inheritance pattern was observed in obtaining 
the required Winnie x Ccr6
-/- 
genotype. Many litters were produced until a working 
population of experimental mice resulted, and these were subsequently utilised for 
experimental purposes whilst maintaining healthy breeding pairs. 
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3.5 Concluding remarks 
 
In this study, generation of a Winnie x Ccr6
-/-
 mouse model and identification of 
homozygous genotype of the same was achieved. An appropriate genotyping technique 
for each mouse strain was optimised and utilised. The respective genotypes were 
confirmed by performing an SNP assay for Winnie mice and PCR followed by agarose 
gel electrophoresis for Ccr6
-/-
mice. Generation of Winnie x Ccr6
-/- 
mice was achieved; 
further assessments of its phenotype and its effects on inflammation in the absence of 
Ccr6 would be a valuable asset in understanding the role of CCR6 in the disease process 
of IBD.  
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Chapter 4 
Clinical assessment and histopathological examination of 
Winnie x Ccr6
-/- 
mice          
 
                                                                    
4.1 Introduction 
 
An important focus of our study was the assessment of the novel model Winnie x Ccr6
-/- 
phenotype. In this chapter, phenotype assessments of Winnie x Ccr6
-/- 
mice pertaining to 
clinical parameters and
 
changes in the histopathology of this strain are outlined. The 
Winnie mice phenotype has been extensively studied based on clinical, histological, 
molecular and immunological aspects, and it is a well-established spontaneous chronic 
colitis model [43,145,175]. It is imperative to validate the phenotype of any experimental 
mouse strain as it ascertains the utility of that animal in the field of biomedical research.  
A systematic approach for the assessment of phenotype of experimental mice which may 
have been genetically altered was outlined by Wood et al. [176]. Primary-level and 
secondary-level assessments were suggested as a guideline to assist in the phenotype 
assessment process of experimental animals, precisely mice or rats. The primary-level 
assessments are basically to identify abnormalities, whilst the secondary-level 
assessments are for quantification and evaluation of abnormalities. Both primary and 
secondary phenotype assessments are vital in studying the current mouse models used for 
investigating diseases in biomedical research [176]. 
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 The phenotype and colitis assessments in Winnie x Ccr6
-/- 
mice were performed based on 
previously established protocols [131]. The specific parameters included the evaluation of 
colon weight, colon length, and colon weight by body weight ratio. Colon weight is 
regarded as a significant indicator of colitis, and the histopathology of colon tissue 
sections and small intestine stained with H&E were examined and graded using a blinded 
grading system developed for intestinal inflammation based on the standard protocol of 
histological scoring for colitis [131,177]. In the present study, the phenotype evaluation 
process noted other general aspects with regard to the experimental animal’s general well-
being as part of the assessment process.  
Ccr6
-/- 
mice were developed to study various diseases such as RA, psoriasis and EAE 
[91,109]. Ccr6
-/- 
mouse models are also considered a very important tool in understanding 
lung and gut diseases. Ccr6 is implicated as a susceptibility locus in CD and the role of 
CCR6-mediated colitis has been advanced by the development of Ccr6
-/-
 mouse models in 
order to study the disease process of IBD in vivo. Due to the absence of Ccr6, the 
development of disease and the alteration of immune responses can be studied by using 
Ccr6
-/- 
mice. Defective leukocyte homeostasis and changes in the cytokine milieu in the 
intestinal mucosa are attributed to the absence of Ccr6 [98]. Winnie, a spontaneous 
chronic colitis mouse model develops mild distal colitis by 6 weeks of age [145].  
Colonic inflammation displayed by the Winnie strain is due to the homozygous missense 
point mutation in the mucin 2 gene (Muc2). The resulting endoplasmic reticulum stress 
leads to the development of colonic inflammation similar to that of ulcerative colitis seen 
in humans [43]. The SNP is the nominal Winnie mutation, and the substitution of cysteine 
with tyrosine in the D3 domain at the N terminus of Muc2 was identified in Winnie mice 
[43]. The goblet cell dysfunction occurs due to the mutation in Winnie mice and, unlike 
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other contrived models, colitis spontaneously occurs in this phenotype as a result. There 
is a significant knowledge gap that exists regarding our understanding of the exact disease 
processes contributing to both UC and CD in IBD. The Winnie mouse model, which 
exhibits colonic inflammation due to a primary epithelial cell defect, ascertains the need 
for the secretion of mucin in order to maintain the integrity of the secretory cell, thereby 
preventing the occurrence of colonic inflammation.  
The crosstalk between the colonic epithelial cells and luminal microbes, followed by the 
mucosal immune responses that occur during the colonic inflammation, needs to be 
addressed in order to understand the disease pathogenesis and progression. The reciprocal 
paracrine interaction of epithelial cells and immune cells in the intestine needs to be 
understood in order to relate or mimic IBD in vivo. The involvement of both the adaptive 
and innate immune system is well showcased in Winnie mice colitis. Hence serves as a 
potential mouse model for spontaneously occurring colitis to explore the role of the Ccr6 
gene in this colitic context. 
 
4.2 Aims/hypothesis 
 
Winnie mice develop mild spontaneous distal colitis due to a primary epithelial defect, 
leading to impairment in goblet cell function. The present study aimed to generate an 
experimental genotype, thereby intended to document physiological changes pertaining to 
colitis and to investigate the initiation and development of inflammation during the 
absence of the Ccr6 gene both clinically and histologically. The hypothesis of this study 
was that Ccr6
-/-
 mice, when crossed with Winnie mice, results in exacerbation of colitis 
due to the absence of the Ccr6 gene. 
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4.3 Results 
 
4.3.1 Assessment of clinical parameters 
 
As part of the clinical assessments, all mice aged 8–12 weeks and of either sex were 
utilised for this study. The body weight of mice (n=9) from all four genotypes (Winnie 
16–20g, Winnie x Ccr6-/- 18–25g, Ccr6-/- 22–28g and WT 19–20g) were noted prior to 
sacrifice. Winnie x Ccr6
-/-
 mice, the experimental mouse model used in this study, were 
compared with the other three groups of mice. The parameters for evaluation of intestinal 
inflammation were based on previously established protocols [131] (Table 4.1). 
The body weight of Winnie x Ccr6
-/- 
mice was compared with WT, Winnie, Ccr6
-/- 
mice 
(Figure 4.1). It was noted that the body weight of Winnie x Ccr6
-/- 
mice were decreased 
(P-value <0.05) relative to Ccr6
-/-
 mice, and the body weight of Winnie mice was 
decreased (P-value <0.001) relative to Ccr6
-/- 
mice. The body weight reduction observed 
in Winnie x Ccr6
-/- 
mice indicates that this could possibly be due to the genetic ablation of 
Ccr6 in Winnie mice. 
 Table 4.1: Protocol for evaluation of intestinal inflammation 
Parameters Procedure/Details 
Body weight Mice weighed prior to culling 
Colon length Measured from the caeco-colic 
junction up to rectum 
 
 
 
Colon weight Weight of wet colon   
Histological colitis scores Blinded grading of H&E stained 
specimens 
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Figure 4.1: Genetic ablation of Ccr6 results in alteration of body weight in Winnie x 
Ccr6
-/-
 mice.  
Body weight of WT, Winnie, Ccr6
-/- 
and
 
Winnie x Ccr6
-/-
 mice aged 8–12weeks was measured 
prior to culling.
  
The body weight between all four genotypes was compared using one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparison tests. A *significance is shown 
by p < 0.05, data represents mean± SEM (n=9 / genotype).   
 
 
4.3.2 Colon length 
 
The large intestine was retrieved from the body cavity of mice and was excised near the 
caeco-colic junction. The colon from Winnie, Ccr6
-/-
, and Winnie x Ccr6
-/-
 was retrieved 
the same way and measured for length from the caeco-colic junction up to the proximal 
rectum. The colon length between the four genotypes did not vary (Figure 4.2A), and 
measurements were the following: WT–7.3 cm, Winnie –7.7 cm, Ccr6-/- – 7.6 cm and 
Winnie x Ccr6
-/- –7.1 cm. The colon length was compared and results did not show any 
difference (Figure 4.2B) between the four groups and failed to achieve a statistical 
significance (n=9 / genotype). 
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Figure 4.2:  Absence of Ccr6 does not alter colon length in Winnie x Ccr6
-/-
. 
A. Colon length was measured from (WT - 7.3 cm, Winnie - 7.7cm, Ccr6
-/- 
- 7.6 cm, Winnie x 
Ccr6
-/-
 - 7.1cm) mice aged between 8–12 weeks.  
B. Colon length between four genotypes was compared using one-way ANOVA and Tukey’s 
multiple comparison tests. Results showed no difference between the four genotypes, (ns) no 
statistical significance was shown, data represents mean± SEM (n=9 / genotype). 
 
 
 
WT- 7.3cm 
Colon 
lenghtC57BL/6J 
colon length -7.3 
cm 
Ccr6-/- - 7.6 cm 
Winnie- 7.7 cm 
Winnie x Ccr6-/- - 7.1 cm 
A. 
B. 
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4.3.3 Colon weight  
 
The wet colon was cut open longitudinally and the faecal contents were removed and 
weighed. The colon weight of each mouse from all four genotypes, WT, Winnie, Ccr6
-/- 
and Winnie x Ccr6
-/- 
mice was noted. The colon weight (Figure 4.3A) of Winnie x Ccr6
-/- 
was significantly increased (P-value < 0.01) relative to Ccr6
-/- 
mice. However, the colon 
weight of WT (P-value <0.001) was lower than the Ccr6
-/- 
mice. The results indicated 
that, in the absence of Ccr6, colon weight was not significantly increased in Winnie x 
Ccr6
-/- 
mice when compared to Winnie mice. The colon weight was analysed for the ratio 
of body weight (Figure 4.3B). The Winnie x Ccr6
-/- 
mice colon
 
exhibited an increase (P-
value < 0.05) relative to Ccr6
-/- 
mice. Winnie mice had an increase in the colon weight 
over body weight ratio (P-value <0.05) relative to Ccr6
-/-
mice. The results suggested that 
in the Winnie x Ccr6
-/-
 phenotype, there was no significant change in the ratio of colon 
weight over body weight due to the absence of Ccr6.  
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Figure 4.3: Increased colon weight and colon weight/body weight ratio in Winnie x 
Ccr6
-/- 
relative to Ccr6
-/- 
mice. 
A. The wet colon was cut opened longitudinally; faecal contents were removed and weighed. The 
colon weight of each mouse from four genotypes, WT, Winnie, Ccr6
-/- 
and Winnie x Ccr6
-/-
 mice 
was noted and compared between them. One-way ANOVA and Tukey’s Multiple Comparison 
test was used, a significance of **p < 0.01, ***p <0.001 was shown, data represents mean± SEM 
(n=9 / genotype).  
B. The colon weights were presented as a ratio of body weight. Means were compared using one-
way ANOVA and Tukey’s Multiple Comparison tests, a significance of *p < 0.05, **p <0.01 was 
shown, data represents mean± SEM (n=9 / genotype).  
 
 
 
A. 
B. 
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4.3.4 Histopathological assessment  
 
Histopathological assessments were performed in a blinded fashion for H&E stained 
colon tissue sections using the grading system (Table 2.7) adapted from Geboes et al. 
[177]. The colon tissue section slides were examined and scored for features of 
inflammation, mucosal lymphoid aggregates, cryptitis and crypt elongation, goblet cell 
loss and crypt architectural changes. The examination of H&E stained tissue sections 
revealed (Figure 4.4) Winnie x Ccr6
-/-
colon was highly inflamed in the proximal colon 
(PC), (P-value < 0.01)   to mid colon (MC) relative to Winnie PC.  
Though the distal colon (DC) in Winnie x Ccr6
-/- 
seemed to appear mildly inflamed (P-
value < 0.001) relative to Winnie mice distal colon. While DC was highly inflamed in 
Winnie mice, the proximal colon (P-value < 0.01) remained mildly inflamed. The Ccr6
-/-
 
mice colon and the WT mice colon, when examined, did not indicate any inflammation 
and appeared to be normal. The mid colon of Winnie x Ccr6
-/-
 was highly inflamed (P-
value < 0.05) relative to the Winnie mice mid colon. The Winnie x Ccr6
-/-
 mice mid colon 
was inflamed (P-value < 0.05) when compared to its proximal colon. 
 Surprisingly, the deletion of Ccr6 had not only exacerbated the colitis but had conferred 
differential distribution of inflammation in Winnie x Ccr6
-/-
. Examinations of colon tissue 
sections revealed goblet cell depletion and reduction in mucus secretion concurrent with 
the Winnie phenotype (Figure 4.6). Colon sections also exhibited inflamed submucosa in 
the proximal colonic segment. Damage to the epithelium and changes in crypt 
architecture such as crypt shortening or crypt distortion were observed in the PC to MC 
regions of Winnie x Ccr6
-/- 
mice (Figure 4.5) Neutrophil infiltrations were observed in the 
glands and an abundance of neutrophils in the tissues indicated active inflammation. An 
abundant presence of neutrophils in the proximal region was detected and reduced 
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numbers of neutrophils in the distal region, as opposed to that, observed in the Winnie 
mice phenotype (Figure 4.8). The occurrence of gland necrosis involving the PC and DC 
of Winnie x Ccr6
-/- 
mice was also detected. The absence of inflammatory cell infiltration 
was observed in the submucosa of the DC. 
Cryptitis was noted in the proximal colon of Winnie x Ccr6
-/-
 and increased inflammation 
was also observed as the presence of crypt abscesses was detected in the mid colon 
segment. Neutrophil infiltration in the proximal colon extending towards the submucosal 
layer in Winnie x Ccr6
-/- 
(Figure 4.7)
 
mice was prominent. Hyperchromatic nuclei 
revealed epithelial damage and were observed in Winnie and Winnie x Ccr6
-/- 
mice. More 
than 50% of goblet cell loss was detected in the Winnie DC along with some discrete 
crypt lesions and abscesses (Figure 4.8). Irregular crypt architecture was observed in the 
Winnie DC (Figure 4.6) and Winnie x Ccr6
-/- 
PC (Figure 4.5). These results indicated an 
increase in inflammation in proximal to mid colonic segments in the Winnie x Ccr6
-/- 
mice phenotype.  
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Figure 4.4: Increased inflammation in proximal to mid colon of Winnie x Ccr6
-/-
. 
H&E stained colon tissue sections were graded using a scoring system for inflammation.  
Combined scores from the proximal colon (PC), mid colon (MC) and distal colon (DC) segments 
are represented in the figure. Results were calculated by one-way ANOVA and Tukey’s Multiple 
Comparison test. A significance is shown by **p < 0.01, ***p < 0.001, data represents mean± 
SEM (n=6/ genotype).  
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Figure 4.5: Comparative proximal colon histology from all genotypes. 
Representative H&E sections of proximal colon displaying the differences in crypt 
architecture, presence or absence of goblet cells in the proximal colon between Wild-type, 
Ccr6
-/-
, Winnie and Winnie x Ccr6
-/-
 mice. Magnification 100x and 400x. 
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Figure 4.6: Comparative distal colon histology from all genotypes. 
Representative H&E sections of distal colon presenting the differences in crypt 
architecture, presence or absence of goblet cells in the distal colon between Wild-type, 
Ccr6
-/-
, Winnie and Winnie x Ccr6
-/-
 mice. Magnification 100x and 400x. 
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Figure 4.7: Increased inflammatory cell infiltration in PC of Winnie x Ccr6
-/- 
mice. 
A, B. Proximal colon of Winnie x Ccr6
-/- 
showing inflammation in the submucosa and 
inflammatory cell infiltration in the lamina propria, goblet cell loss, crypt distortion.  
Magnification is 400x and 100x. 
A. 
B. 
400 x 
100x 
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Figure 4.8: Increase in leucocytes in the lamina propria in the distal colon of Winnie. 
A, B. Prominent increase in leucocytes in the lamina propria, mild cryptitis, indicated by a mild 
distortion and elongation of the glands. Magnification 200x. 
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4.4 Discussion 
 
Inflammation observed in the Winnie x Ccr6
-/-
 mice progressively increased in severity 
from the distal to the proximal segment of the colon. In Winnie and Winnie x Ccr6
-/- 
mice, the colon was observed to be swollen, and thickened relative to wild-type and Ccr6
-
/-
 mice. Unlike Winnie mice, the thickening of colon observed in Winnie x Ccr6
-/- 
mice 
was most prominent in the caeco-colic region. Thickening of the colonic wall associated 
with colonic inflammation likely contributed to the increase in the colon weight of mice 
harbouring inflammation (Winnie and Winnie x Ccr6
-/-
) [43,145]. Histopathological 
assessment of Winnie and Winnie x Ccr6
-/- 
mice
 
revealed
 
all the classical symptoms of 
colitis such as crypt distortion, cryptitis, erosion, submucosal inflammation, and 
ulceration.  
Hyperchromatic nuclei were observed in the proximal colon of Winnie x Ccr6
-/- 
mice, 
suggesting the development of more severe pathological changes in this phenotype. The 
distribution of inflammation seen during histopathological grading in Winnie x Ccr6
-/-
 
emphasises an altered distribution of inflammatory leucocytes and cytokines compared to 
Winnie. The Winnie mouse model is remarkable in that colitis develops whilst the 
underlying immune system is normal [178]. Due to the presence of an unmodified 
immune system in the Winnie mouse strain, it is easier to interpret pathological changes 
resulting from genetic deletion of Ccr6. Ccr6
-/- 
mice display underdeveloped intestinal 
Peyer’s patches (PPs), an increased number of intra-epithelial lymphocyte (IEL) 
subpopulations and defective leukocyte homing to the intestinal mucosa [137,179].  
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The inflammation of the Winnie x Ccr6
-/- 
model occurs primarily in the proximal colon so 
a defective leukocyte dynamic would likely be most pronounced here. In the Winnie x 
Ccr6
-/- 
model we demonstrate spontaneous inflammation in the proximal colon to mid 
colon segment and mild inflammation in the distal colon of this phenotype.  
In this study, a Winnie x Ccr6
-/-
 mouse model was used to assess and analyse the 
development of the disease and their response to the inflammatory environment when 
compared with that of human colitis. In Winnie mice, due to the missense mutation, the 
effect is limited to intestinal secretory cells whereas the underlying immune system 
remains unaffected. Similar to other models of colitis, the lamina propria of the distal 
colon in Winnie mice displays a cytokine profile dominated by IL-17A and IFN-γ 
production from CD4
+
 lymphocytes. The characteristic differences in the immune 
regulation of Winnie mice and Ccr6
-/- 
mice could be the reason for the outcome of the 
inflammatory pattern observed in Winnie x Ccr6
-/- 
mice. Although a large number of 
inflammatory infiltrates did not increase as age-progressed to 12 weeks in both Winnie 
and Winnie x Ccr6
-/-
, the abundant inflammatory cell infiltration was mostly confined to 
the PC to MC segments in Winnie x Ccr6
-/- 
mice. Neutrophils are recruited into the 
intestinal mucosa during an active inflammatory response which was observed in the 
Winnie x Ccr6
-/- 
model.  
The differential exacerbation demonstrated in the Winnie x Ccr6
-/- 
mice colon might be 
due to the increased production of pro-inflammatory cytokines in the site of exacerbation 
[43] as Winnie mice have reportedly higher expression of pro-inflammatory cytokines 
such as IL-β, during intestinal inflammation [43]. Multiple factors are involved in the 
development of intestinal inflammation, specifically, the activation of NF-κB is said to be 
central during the development of inflammation. ER stress induces the activation of NF-
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κB, and the transcription is increased as a result [43]. The pro-inflammatory cytokine 
IL ̶1β is elevated and increased in the intestines of both UC and CD patients and this is 
also observed with our Winnie colitis model [43,145]. The elevated expressions of T 
effector cells, in particular Th17 cells and associated cytokines such as IL-17 and IL-23 
identified in Winnie mice demonstrates a dominant Th17 immune response resembling 
UC in humans [43,145]. Th17 effectors also promote neutrophil chemotaxis, and hence a 
mucosal neutrophilia could be expected in Winnie x Ccr6
-/-
. CCR6 has been implicated in 
skewing the response in intestinal inflammation towards exacerbation or homeostasis 
based on the cytokine milieu. The IL-23/Th17 immune response demonstrated in Winnie 
mice is reportedly one of the major factors in the pathogenesis of IBD [180,181]. 
In Winnie x Ccr6
-/-
 mice, the significant role of effector T cells in dictating the 
exacerbation of Winnie colitis and the activation of innate immune response in younger 
age Winnie mice were reported by Heazlewood et al. (2008). The differential 
inflammatory pattern observed in the colonic segments of Winnie vs Winnie x Ccr6
-/-
 
during histopathological inflammation demonstrates the crucial role of T cells in this 
phenotype. In Winnie mice, the balance between Th17 and Treg in sections of the colon 
determines the inflammatory phenotype and absence of Ccr6 could possibly contribute to 
the change in the equation of Th17 and Treg differentially attributing to the outcomes 
observed in the Winnie x Ccr6
-/- 
phenotype.  
 
The pathology of Winnie x Ccr6
-/-
 is in contrast to the pathology of Winnie colitis. Mild 
distal colitis develops in Winnie mice by 6 weeks of age and advances into a severe and 
chronic colitis as age progresses [131,182]. The clinical and histopathological features of 
Winnie colitis is similar to UC observed in human patients [43]. Characterisation of 
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inflammatory cell infiltrates can be conducted by using immunohistochemistry 
techniques. The use of colocalization assays would be advantageous in identifying Ccr6 
and Ccl20 positive cells in the lamina propria of Winnie and Winnie x Ccr6
-/-
 mice. This 
is a limitation of this study and must be considered in future studies.   
In Ccr6
-/- 
mice, colitis was induced by DSS and TNBS respectively. The histopathological 
results showed the absence of ulcers which suggested a reduction in the severity of 
intestinal pathology in the DSS-induced mouse model and susceptibility in the TNBS 
model which is otherwise resistant to intestinal inflammation [137]. As there is an 
increased existence of T cell subsets in the intestine of Ccr6
-/- 
deficient mice when 
combined with the Winnie strain, the arising genotype would be expected to have a 
homeostatic or inflammatory phenotype [25,137].   
Rectal prolapse in Winnie x Ccr6
-/-
 mice was uncommon, with only a very small number 
of female Winnie x Ccr6
-/-
 mice developing rectal prolapse at around 8–12 weeks. Winnie 
mice were reported to be prone to developing rectal prolapse associated with intestinal 
inflammation. However, only some of the Winnie mice have been reported to develop 
rectal prolapse and although there has been no specific age reported to date, it could occur 
at any time between 9–20 weeks [183].  
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4.5. Concluding remarks 
  
In summary, the clinical assessment along with a histological examination of the Winnie 
x Ccr6
-/- 
colon displayed exacerbation of inflammation in the PC to MC segment. In 
Winnie mice, the DC was inflamed and the PC remained mildly inflamed which was in 
correlation with previous findings. The Ccr6
-/- 
mice colon and the WT mice colon were 
both non-inflamed and appeared to be normal. Overall, the Winnie x Ccr6
-/-
 mouse model 
displayed a differential pattern of inflammation which could possibly be due to the 
recruitment of pro-inflammatory cytokines. Further characterisation of the Winnie x  
Ccr6
-/- 
model based on molecular and immunological expression in the forthcoming 
chapters will provide a better understanding of this model.  
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Chapter 5 
 
Immunological and Molecular Profile of  
Winnie x Ccr6
-/-
 mice  
 
 
5.1 Introduction 
 
The immunological, molecular and cytokine profiles of Winnie x Ccr6
-/-
 mice are 
described in this chapter. The cytokine environment and their responses are the main 
elements responsible for the initiation of inflammation in IBD. Intestinal immune 
responses initiate a cascade of events due to an inflammatory signal, and differentiated T 
and B cells along with the cytokine environment decide whether homeostasis or 
inflammation proceeds [184]. It is important to identify these immune mechanisms to 
establish a clear-cut definition of IBD pathogenesis in order to develop better treatment.  
Chemokines and chemokine receptors are now the novel therapeutic targets [75] as they 
play a vital role in the immune system, in particular, they are involved in lymphocyte 
homing during homeostasis and inflammation [67,185]. Chemokine receptors organise 
the cells within lymphoid tissues and also the expression of other receptors in myeloid 
cells such as dendritic cells, and regulate their trafficking activities [186]. CCR6 is 
expressed on both Treg cells and Th17 cells; it serves as a distinct marker in 
differentiating both from the other types of T helper cells [103,109]. CCR6 is involved in 
B cell differentiation and humoral immunity. CCL20, the chemokine ligand for CCR6, is 
abundantly seen to be produced by colonic epithelial cells, dendritic cells and 
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subepithelial fibroblasts [94,187]. The presence of CCR6 on the surface of both anti-
inflammatory Treg cells and pro-inflammatory T helper cells suggest dual functions, both 
enhancing inflammation and limiting its severity or extent. The interaction between 
chemokine and ligand in both the activation and resolution of colitis require further 
definition in order to understand the pathological skewing toward chronic inflammation. 
Ccr6
-/- mice display underdeveloped Peyer’s patches and due to this, the myeloid CD11b+ 
CD11c
+
 dendritic cell subset positioning is absent from the subepithelial dome. A diverse 
range of T cell subpopulations are expressed within the intestinal mucosa and are 
involved in intestinal immunity [137].  
It is now established that Ccr6 is important for recruitment and/or migration of both Treg 
cells and Th17 cells during inflammation and specifically during intestinal immune 
responses, and hence the Ccr6
-/- 
mouse model was widely used to understand the role of 
Ccr6 in intestinal inflammation [137]. Previous studies have reported that CCR6
+
 cells 
were more often identified in CD4
+ 
T cell subsets than in CD8
+ 
T cells subsets [187].  Of 
the CD8
+
 CCR6
+
 T cells, most were found to display a T effector memory (TEM) 
phenotype [187]. Ccr6 is highly expressed in immature dendritic cells and some studies 
using Ccr6
-/- 
mice have demonstrated defects and the impaired dendritic cell presentation 
to CD4
+
 T cell populations in the Peyer’s patches which emphasises the importance of the 
CCR6 gene in mucosal immunity [99,187,188].  
Genome-wide association studies reported that the IL-23/Th17 pathway plays a vital role 
in IBD pathogenesis and the genetic polymorphisms of Th17 signature genes IL23R, IL-
12B (p40), CCR6 and STAT3 are reportedly associated with the initiation of both CD and 
UC [145]. In Winnie mice, dendritic cells (DCs) and macrophages, the antigen presenting 
cells (APCs), initiate an innate immune inflammatory response which is followed by 
  
W. BASHEER 
GENETIC ABLATION OF Ccr6 CONFERS DIFFERENTIAL EXACERBATION IN A SPONTANEOUS COLITIS MODEL   81 
 
adaptive immune responses which progress toward a mixed Th1, Th2 and a more 
conspicuous Th17 mucosal immune response. The distal colon of Winnie mice featured 
increased levels of CD11c
+ 
APCs and activated dendritic cells DCs (CD11c
+ 
MHC-11
hi
) 
which also assists in configuring a Th17-dominated mucosal immune response [43,145].  
5.2 Aims/hypothesis 
 
The aim of this present study was to identify the immunological, molecular and cytokine 
profile of Winnie x Ccr6
-/- 
mice. Since Winnie x Ccr6
-/-
 mice immunopathology needed 
to be described, we hypothesised that there will be an increased expression of Th17 
signature genes and increased the population of CD4
+
IL-17
+
 T effector subsets in the 
absence of CCR6. 
5.3 Results 
 
5.3.1 Gene expression   
 
A panel of inflammatory markers was chosen (Table 2.4) and gene expression assays 
were performed as described previously. Gene expression of the inflammatory markers 
was evaluated, normalising the data to Eef2 (housekeeping gene) (Figure 5.1). Expression 
of pro-inflammatory Il-1β in the proximal colon segment of Winnie x Ccr6-/- mice was 
increased (P value < 0.01) compared to the proximal colon of Winnie mice.  
In contrast, Ccr6 deletion in Winnie mice did not discernibly alter Il-6 levels in the 
proximal colon, whereas Il-6 levels in the distal colon were increased (P value < 0.05) in 
Winnie x Ccr6
-/- 
mice. The expression of Il-6 varied in the distal colon compared to the 
proximal colon of Winnie x Ccr6
-/-
 mice. A decrease (P-value < 0.001) in the expression 
levels of Tgf-β1 was observed in both the proximal and distal colon of Winnie x Ccr6-/- 
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mice when compared with the distal colon of Winnie mice. An increase (P-value < 0.001) 
of Ccr6 levels were observed in the Winnie mice distal colon when compared to its 
proximal colon. In Winnie x Ccr6
-/-
 mice, the Ccr6 gene was not expressed as we 
expected which additionally affirmed the homozygous gene deletion, and a statistical 
significance (P value < 0.001) was reached relative to Winnie mice. Ccl20 expression was 
increased (P value < 0.001) in the proximal colon of Winnie x Ccr6
-/-
 mice and distal 
colon of Winnie mice. On the other hand, Ccl20 levels were reduced (P-value < 0.001) in 
the proximal colon of Winnie mice and in the distal colon of Winnie x Ccr6
-/-
 mice.  
Il-22 levels were significant (P-value < 0.001) in the distal colon of Winnie x Ccr6
-/-
 mice 
compared to its proximal colon and also when compared to the Winnie mice distal colon, 
Il-22 had reduced (P-value < 0.001) in the distal colon.  Il-23a expression was decreased  
(P-value < 0.001) in the distal colon of Winnie x Ccr6
-/-
 mice and in contrast significant  
(P-value < 0.001) levels were observed in the distal colon of Winnie mice. Foxp3 
expression levels were varied (P-value < 0.01) in the proximal colon of Winnie x Ccr6
-/-
 
mice when compared to the significantly increased expression observed in the distal 
colonic segment of Winnie mice. Il-10 expression was significantly reduced (P-value < 
0.05) in the distal colon of Winnie x Ccr6
-/-
 mice, when compared to the Winnie mice 
distal colon and this relates to the milder inflammation, observed histologically in the 
distal colon of Winnie x Ccr6
-/-
 mice. 
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Figure 5.1 Relative gene expressions in the proximal and distal colon of Winnie and 
Winnie x Ccr6
-/-
 mice. 
The relative gene expression of inflammatory markers between proximal and distal colon samples 
of mice in all four genotypes was used and was amplified as 25ng of the template in duplicates 
and normalised to the housekeeping gene Eef2 and quantified using 2
-∆∆
CT. Results were 
analysed using one-way ANOVA and Tukey’s multiple comparison tests to compare the proximal 
and distal colon samples between the four genotypes. A significance is shown by *p < 0.05, 
**p<0.01, ***p<0.001, data represents mean± SEM of (n=3/ PC and DC from each genotype). 
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5.3.2 Effect of CCR6 deficiency on CD4
+
T cells in Winnie x Ccr6
-/-
 mice 
 
In the samples from WT, Winnie, Ccr6
-/-
 and Winnie x Ccr6
-/- 
mice the lymphocyte 
population was first identified and gated for and then the singlet populations were 
isolated. The B cells and T cells were identified by their markers B220 and TCR 
respectively before being identified and gated. CD4
+
 T cells in both MLNs and spleen 
samples were then analysed on the flow cytometer and assessed. There was a statistically 
significant decrease (P value<0.01) of the CD4
+
 T cell population in MLNs of Winnie x 
Ccr6
-/-
 mice and Winnie mice (P <0.05) when compared with Ccr6
-/-
 mice. WT spleen 
samples displayed no statistically significant differences in the size of the CD4
+
 T cell 
population between all four genotypes (Figure 5.2A). The CD4
+
 and CD8
+
 T cell 
subpopulations in MLNs were reduced in Winnie x Ccr6
-/- 
mice relative to WT, Winnie, 
and Ccr6
-/-
 mice (P-value < 0.05). The activated IL-17
+
FOXP3
-
 cell population in Winnie 
was relative to Ccr6
-/-
 (which was around P <0.05) and it was statistically significant. On 
the other hand, an increasing trend of IL17
+
FOXP3
+
 T cells in MLNs of Winnie x Ccr6
-/-
 
was observed but regarded as not statistically significant.  
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Figure 5.2 Quantification of CD4
+
 T and CD8
+ 
T cells in Winnie x Ccr6
-/-  
 
A. The frequency of CD4
+ 
T cells
 
to
 
CD8
+ 
T cell population was quantified in both spleen and 
MLNs. 
B. Mesenteric lymph nodes (MLNs) were retrieved along with spleen from all four genotypes and 
stimulated and stained before being analysed by flow cytometry. The lymphocyte populations (T 
and B cells) were identified and CD4
+ 
T cells were then identified. IL17
+
FOXP3
+
, IL17
-
FOXP3
-
, 
IL17
-
FOXP3
+
, IL17
+
FOXP3
-
 cells were identified and quantified from the CD4
+ 
T cell 
population. The frequency of lymphocytes was quantified from MLNs.  
C. B
C. 
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C. Splenocytes were isolated, lysed, processed, stimulated and intracellular stained to identify the 
CD4
+
T cells. IL17 and FOXP3 populations were identified and quantified from CD4
+
Tcell 
population.  
Figure 5.2 A/B/C represents data generated from 2 independent experiments (n=3/genotype). 
One-way ANOVA & Dunn’s multiple comparison tests, *significant at p <0.05. 
 
 
5.3.3 Assessment of CCR6 expression profile in Winnie x Ccr6
-/-
 mice 
 
MLNs and splenocytes were harvested from WT, Ccr6
-/-
, Winnie and Winnie x Ccr6
-/-
 
mice and were stimulated in vitro for 4 hours prior to fixation, permeabilization and 
intracellular staining. The samples were subsequently analysed by flow cytometry and 
there was found to be no statistical significance (Figure 5.3A) between the four groups. 
Data revealed the expression pattern of Foxp3
+
 T cells and IL-17A
+
 T cell population in 
Winnie x Ccr6
-/-
 mice. The MLNs from Winnie x Ccr6
-/-
 showed a decreased (P-value 
<0.05) population of CD4
+
 IL17
+
 FOXP3
+ 
T cells expressing Ccr6 relative to Winnie 
(Figure 5.3B). There was a statistically significant reduction observed in the 
Ccr6
+
FOXP3
-
 Treg cells and Ccr6
+
IL17
+
 Th17 (P-value <0.05) in Winnie and Ccr6
-/-
 
MLNs.  
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Figure 5.3: Quantification of Ccr6 expression in CD4
+
 T cell subsets in MLNs.  
A. The Ccr6 expression on CD4
+
 T cells from MLNs and splenocytes of WT, Ccr6
-/-
, Winnie and 
Winnie x Ccr6
-/-
 mice, data represents no significance between the four groups (n=3/genotype), 
data pooled from 2 independent experiments.  
B. MLNs removed from WT, Ccr6
-/-
, Winnie and Winnie x Ccr6
-/-
 mice were stimulated in vitro 
for 4 hours prior to fixation, permeabilization and intracellular staining. The MLNs were 
intracellularly stained using BD fix perm kit. Mean fluorescent intensity (MFI) of Ccr6 was 
quantified from 2 independent experiments (n=3/gentoype). One-way ANOVA, Dunn’s multiple 
comparison tests,*significant at p <0.05. 
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Figure 5.4: Quantification of Ccr6 expression in splenocytes.  
Splenocytes removed from WT, Ccr6
-/-
, Winnie and Winnie x Ccr6
-/-
 mice were stimulated in 
vitro for 4 hours prior to fixation, permeabilization and intracellular staining. Mean fluorescent 
intensity (MFI) of CCR6 was quantified from 2 independent experiments (n=3/genotype). One-
way ANOVA, Dunn’s multiple comparison tests, *significant at p <0.05. 
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5.3.4 Cytokine profile and T cell expansion assay of Winnie x Ccr6
-/- 
mice 
 
Cytokine assays were performed on colonic explant cultures and the results revealed that 
the proximal colon of Winnie x Ccr6
-/- 
mice showed an increased expression of IL-1β 
when compared to the Winnie mice distal colon. Also, the expression of IFN-γ was 
reduced in the proximal colon and increased in the distal colon of Winnie x Ccr6
-/- 
mice. 
In
 
Winnie mice, the proximal colon showed an increased (P value < 0.01) level of IFN-γ 
and a decreased level in the distal colon. Winnie x Ccr6
-/- 
mice had
 
lower levels of IL-
17A in the proximal colon but an increase in the distal colon explant sample was 
observed, whereas Winnie mice displayed a decreased expression of IL-17A in both distal 
and proximal colonic explant cultures. These results were statistically non-significant 
(Figure 5.5). 
A T cell expansion assay was performed in vitro, and the MLNs were retrieved and cells 
were isolated from WT, Winnie x Ccr6
-/- 
, Winnie and Ccr6
-/- 
mice and
 
were cultured at a 
cell concentration of 2 x 10
6 
/ mL, activated with anti-CD3 and anti-CD28 for 24 hours 
and IL-17A cytokine levels were significantly increased relative to Ccr6
-/- 
(shown at P 
<0.05) (Figure 5.6). 
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Figure 5.5 Increased IL-1β in colonic explant culture in Winnie x Ccr6-/- mice.  
The colonic explants from Winnie and Winnie x Ccr6
-/-
 proximal and distal colon samples were 
cultured for 24 hours. The supernatants were assessed for cytokine levels using Milliplex assay 
kit. Cytokine levels in the supernatants were normalised to tissue weight and obtained pg/ml of 
cytokines/gm of tissue. The figure represents data from 2 experiments pooled together; median 
fluorescence was calculated and the results did not reach a statistical significance. One-way 
ANOVA, Dunn’s multiple comparison tests, **significant at p < 0.01. 
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Figure 5.6   Alterations in activated T cells in Winnie x Ccr6
-/- 
mice.  
T cell expansion in vitro T cell stimulation assay, a concentration of 2x10
6 
/ ml cells was cultured 
with anti-CD3 and anti-CD28 for 24hours. The figure represents data (n= 5 / genotype) from IFN-
γ, IL-17A, IL-10 producing T cells which were analysed by one-way ANOVA (non-parametric), 
Dunn’s multiple comparison tests, *significant at p < 0.05.                         
 
5.4 Discussion 
 
The immunological, molecular and cytokine profile of Winnie x Ccr6
-/- 
mice was 
analysed in this chapter to understand the underlying immunopathology. The first step 
was to analyse the gene expression in order to identify and understand the differential 
pattern of colitis observed in Winnie x Ccr6
-/- 
mice. A panel of inflammatory markers 
genes, namely Il-1β, Il-10, Il-23, Il-22, Il-6, Tgfβ1, Ccr6 and Ccl20, were utilised to 
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understand the course of immune-mediated events and the subsequent immune responses 
and chemokine patterns involved, resulting in colitis in the differential pattern in the 
histopathological evaluation process. The immunopathology in Winnie mice is well 
established and features a possible Th17-mediated immune response to an intestinal 
epithelial dysregulation driven by Muc2 mutation. Genetic ablation of the Ccr6 gene in 
Winnie mice resulted in a marked increase in the abundance of Il-1β and Ccl20 mRNA 
transcript in the proximal colon.  
Cytokine assays confirmed a corresponding increase in total IL-1β in the proximal 
colonic explant cultures. Increased production of the pro-inflammatory cytokine IL-1β in 
the proximal colon of Winnie x Ccr6
-/-
 mice was consistent with the pronounced 
exacerbation of inflammation observed during the clinical and histological evaluation. 
Significantly increased expression of IL-1β cytokine in cultured colonic explants has been 
reported in Winnie mice when compared with WT mice [145]. Increased expression of 
IL-1β in our mouse model is consistent with increases also reported in both UC and CD 
in humans [145]. Interestingly, Ccl20 had increased abnormally in the inflamed proximal 
colon but actually seemed to be reduced in the distal colon relative to Winnie mice, 
suggesting that the bulk of Ccl20 produced in the inflamed distal colon of Winnie mice is 
produced by CCR6 cells or is dependent on their factors, such as IL-17 and TNF-α [90].   
Expression of Il-6 and Il-22 were both increased in the distal colon of Winnie x Ccr6
-/-
 
mice whereas Foxp3, Il-10 and Il-23a decreased in the same tissue. IL-22 is a unique 
cytokine produced by immune cells and this cytokine plays a vital part in host defence 
mechanisms at mucosal surfaces and is also involved in tissue restoration. IL-22 is 
beneficial to the host in various infectious and inflammatory conditions, although it 
depends on the target tissue to be pathogenic. Due to its inherent pro-inflammatory traits, 
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when exerted with other pro-inflammatory cytokines, IL-17 is proven to play a major role 
in inflammatory diseases [189-191]. IL-17 producing T cells were reduced when 
compared to Winnie mice in our findings; however, Ccr6 deletion is known to alter the 
frequency of IL-17A
+
 T cells [192]. 
Production of IL-22 by Th17 cells is greater than the amounts produced by 
undifferentiated Th0 cells or Th1 cells [189]. It has been discovered that IL-6, by itself or 
along with TGF-β, has been reported to be essential for the induction of IL-17 in naïve T 
cells [193]. TGF-β has reportedly been shown to suppress production of IL-22 in a dose-
dependent manner [189,193,194]. TGF-β is involved in the Th17 differentiation in the 
presence of IL-6 and hence increased expression of inflammation was observed in our 
current study. This is probably due to its anti-inflammatory trait which could possibly 
result in a reduction of inflammation [195].  
Therefore the increased expression of IL-22 observed in Winnie x Ccr6
-/-
 mice are 
consistent with the predicted Th17-mediated mucosal response in this phenotype. As 
previously reported, the high expression of IL-6 in Winnie mice colonic explant cultures, 
along with IL-12/ 23p40, indicated a Th17-mediated mucosal response [145]. The 
signature cytokines of Th17 expression observed in Winnie x Ccr6
-/-
 mice indicate that 
the Th17 mucosal response could possibly characterise the proximal [189] colitis 
perceived in this phenotype, although IL-17 is not increased and IL-23A seems to be 
unaffected by the absence of Ccr6 (Figure 5.7). IL-23/Th17 dominated mucosal immune 
response in Winnie reported in the literature was not concurrent with our findings in 
Winnie x Ccr6
-/- 
proximal colitis [145,180]. The alterations in cytokine expression in 
Winnie x Ccr6
-/-
 could possibly be due to varied animal housing conditions [43]. The 
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findings need to be further dissected to affirm Th17 dominated mucosal response in 
Winnie x Ccr6
-/-
.   
 
Figure 5.7: Genetic ablation of Ccr6 increases IL-1β and IL-10 in the proximal and 
distal colon of Winnie x Ccr6
-/- 
mice. 
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The immunological parameters of Winnie x Ccr6
-/-
 mice were assessed and CD4
+ 
T cell 
subsets following stimulation from MLNs and spleen were analysed. Treg cells are 
known to be involved in gut immune tolerance and proceed to offer tolerogenic control in 
murine colitis models, where the accumulation of FOXP3
+ 
Treg cells are defined in 
various chronic inflammatory disorders. However, in our study, the CD4
+ 
T cells were 
identified and specifically Ccr6
+
 FOXP3
+
 T cells and Ccr6
+ 
IL17A
+
 Th17 cells were 
identified. FOXP3 cells were decreased which was in line with qPCR findings, the ratio 
of IL-17A
+ 
FOXP3
+
T cells in the absence of Ccr6 deletion needs to be studied further. 
Reduction of CD4
+
FOXP3
+
 Tregs observed in our findings affirms the importance of 
innate immunity and the immune cells involved. It was previously suggested that in 
Winnie mice the balance between Th17 and Treg cells could possibly determine the 
inflammatory phenotype and that the absence of Ccr6 in Winnie x Ccr6
-/- 
mice possibly 
facilitates a variance of pattern in colitis severity, which was observed.  
Either a reduction of CD4
+ 
FOXP3
+
 Treg cells or suppression of efficient 
immunosuppression in Winnie x Ccr6
-/-
 mice may be crucial in down-regulating the 
inflammation of the colon [145]. Increased expression of Ccl20 in Winnie x Ccr6
-/- 
mice 
corroborates the expression of both Ccr6 and Ccl20 in experimental murine colitis models 
as established in previous studies [25,95]. The follicle-associated epithelium is an 
important CCL20 producer for maintaining the GALT [98]. Ccr6 possibly takes on a 
regulatory role as it has been previously reported and contributes to the regulation of IL-
10 production in a steady state, and selectively migrates to the colon while the 
inflammation proceeds [95]. Hence, this study concludes that possibly CCR6 expression 
by Treg cells could potentially play a role in conferring Treg cells the ability to mediate 
immune regulation via anti-inflammatory cytokines such as IL-10 to the inflamed distal 
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colon. Novel colon homing, IL-10 derived from Ccr6
+
 Tregs decreases the severity of 
distal colitis in Winnie x Ccr6
-/- 
mice [95,144,145,196].   
Previous studies have reported that IL-10 is preferentially induced by lamina propria 
macrophages whereas DCs facilitate the differentiation of Th17 cells [195]. In a similar 
fashion, we presume that the IL-10 expression found in the distal colon of our mouse 
model Winnie x Ccr6
-/-
 would possibly promote immune-modulatory function, restricting 
the inflammation in this colonic segment in particular and thereby ameliorating the 
inflammation.  
The well-established immune-modulatory functions of IL-10 and its associated signalling 
modules could serve as mediation for disease regulation especially in the gut as this 
environment favours the production of IL-10 and provides tolerance to commensal 
microbiota, whereas inflammatory responses are modulated in peripheral tissues during 
infections [195,196]. 
Earlier studies  of Winnie mice reportedly identified that due to ER stress the DCs and 
epithelial cells activate and discharge cytokines such as IL-1β, IL-23 and IL-6, and are 
involved in mediating Th17 and Th1 immune responses subsequently followed by the 
release of IFN-γ and IL-17, and this is consistent with our current findings [145].  
IL-10 and TGF-β1 generating Treg cells become overwhelmed by the pro-inflammatory 
responses and these proceedings initiate a sequence of intestinal inflammation.  Increased 
expression of Il-1b in Winnie x Ccr6
-/-
 mice is similar to that of the Winnie mice distal 
colon [175]. DCs produce Il-6 and Il-23a with a Th17 favouring chemokine milieu when 
stimulated, and an increased mRNA expression of Tgfβ1, Il17 and Ccr6 in Winnie mice 
portrayed a Th17 immune response. In Winnie x Ccr6
-/- 
mice, the colitis demonstrated is 
thought to be a multi-cytokine mediated inflammation and proves to be consistent with 
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the colitis observed in Winnie mice except for the differential pattern conferred by the 
genetic ablation of Ccr6.  
 
5.5 Concluding remarks 
 
The immunological, molecular and cytokine profile of Winnie x Ccr6
-/-
 mice was 
associated with the pattern observed with the clinical and histological findings. Immuno-
phenotyping of stimulated colonic lymphocytes indicated a reduction in the FOXP3
+
 
Tregs and increased Th17 cells in the MLNs, but the splenic populations remained 
unaffected in the absence of Ccr6, which is in contrast to current literature. Cytokine 
assays and gene expression assays affirmed and revealed increased expression of pro-
inflammatory cytokine IL-1β which was correlated with the clinical and histopathological 
findings. An increased level of IL-10 expression in the distal colon of Winnie x Ccr6
-/- 
mice was also observed, and this suggests IL-10 mediated amelioration of colitis which 
would otherwise exist in the Winnie mice as reported by Eri et al. and Wang et al. 
[145,180]. In comparison to Winnie colitis, all the above findings conclude that the 
spontaneous colitis demonstrated in Winnie x Ccr6
-/-
 mice in the absence of Ccr6, 
displayed an exacerbated proximal colitis and ameliorated distal colitis in a spontaneous 
manner. 
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Chapter 6 
General Discussion  
 
 
IBD is a multifactorial, immune-mediated disorder, characterised by intestinal 
inflammation where CD and UC are the two subtypes. Genome-wide association studies 
have linked a number of significant loci involved in contributing to the disease 
progression of both CD and UC. Ccr6 is one of the important loci implicated in IBD and 
it has widely been accepted that Ccr6 is involved in both immune tolerance and 
inflammation in the gut. CCR6, along with its ligand CCL20, is involved in mucosal 
adaptive immunity and directing T cells to the inflammation site. There exists a 
knowledge gap between the extent and the balance of the relevant influences that Ccr6 
imparts to the immune system during inflammation/homoeostasis.   
To facilitate the understanding of the pathophysiological course of IBD and to assess the 
novel therapeutic strategies related to exact mechanisms, knockout mouse models were 
developed. The availability of knockout and transgenic mouse models outlining the exact 
pathways associated with the development of both CD and UC is useful in the 
development and evaluation of therapy for IBD (Table 6.1). Currently available animal 
models are either chemically induced or genetically engineered models representing 
either CD or UC for determining the underlying pathogenesis of the disease. This will 
assist in designing experiments for the development of various therapeutic approaches in 
IBD.   
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Table 6.1 IBD Mouse models specific to CD and UC involved in therapeutic research 
Mode of induction  CD UC 
Chemical  TNBS 
 Indomethacin 
 DSS 
 TNBS  
 Oxazolone 
 Acetic acid 
 Sulfhydryl inhibitors 
Transgene/knockout  SAMP1/YitFc 
 N-cadherin 
dominant 
negative mutant 
 TNF∆ARE 
 TCRα-/-  
 WASP-/- 
 Mdr1a-/- 
 IL-2-/- 
 Gαi2-/- 
 IL-7 Tg 
 TRUC(Tbet-/-XRag2-/-) 
 TGFβRIIDN 
 C3H/HeJBir 
                                                                      Adoptive transfer 
Adapted from references [197,198] 
(Table 6.1) Abbreviations: ΔARE, a deletion mutant in AU-rich elements; DSS, dextran sulfate sodium; 
Gαi2, guanine nucleotide-binding protein G(i) subunit α-2; IL, interleukin; Mdr1a, multiple drug resistance 
1a; TCR, T-cell receptor; Tg, transgenic; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumor necrosis 
factor; TRUC, T-bet(−/−)RAG2(−/−) ulcerative colitis; WASP, wiskott–Aldrich syndrome protein; TGF, 
transforming growth factor. 
The chemically induced TNBS mouse model of colitis reportedly did not reiterate the 
aetiopathogenesis of CD although the relevant involvement of NOD2, a susceptibility 
gene in CD, was related to the disease development in this model [199]. However, the 
indomethacin model displayed extensive mucosal injury and mesenteric margins were 
identified as susceptible to CD [197,200]. In the commonly used DSS model for UC, 
colitis is indirectly caused by injury to the epithelium and elicits inflammation. Several 
doses of DSS need to be administered to depict chronic changes as seen in human patients 
and increased variability in disease severity are seen in this model.  
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Therapeutic interventions such as gene/cell therapy, chemical and microbial therapy, have 
been effective in this model [119,197,201]. The TNBS-induced colitis model displays a 
Th2 immune response and closely mimics CD. The oxazolone-induced colitis model also 
displays a Th2 immune response and showcases all the classic symptoms of UC. 
Therapeutic interventions such as Simvastatin have been tested on these two mouse 
models although the outcomes were opposing [197,202]. Acetic acid imparts injury to the 
mucosal epithelium, thereby inducing colitis resembling UC. Reports suggest that the 
acetic-acid model is suitable for drug-efficacy testing and compounds targeting reactive 
oxidative species and confer amelioration. However, this mode of induction needs to be 
tested at different time points, as the one elicited prior to 24hrs is not immunological 
[202].  
Transgenic/knockout models such as SAMP1/YitFc and TNF
ΔARE
 are animal models 
resembling CD, and IL-7 Tg mice, TCRα-/-, WASP-/-, Mdr1a-/- and IL-2-/- are some 
examples of animal models for UC [197,198]. These genetically engineered models are 
involved in drug efficacy assessments. SAMP1/YitFc and TNF
∆∆RE 
are two spontaneously 
occurring mouse models of CD, demonstrating a remarkable similarity to the human 
condition by disease manifestation, histological presentation and the response to current 
treatments [203,204]. These two murine models are used for the development of novel 
therapeutic strategies for chronic ileitis, as it reportedly responds well to conventional 
anti-inflammatory and immunosuppressive treatments [203].  
N-cadherin-dominant negative mutant mice develop CD-like transmural inflammation in 
the jejunum [133,205]. Cadherins are involved in development and facilitate cell 
adhesion. These mice are utilised to identify their role in intestinal inflammation and 
intestinal neoplasia [205]. 
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TCRα-/- is a Th2-mediated spontaneous chronic colitis model which closely resembles 
UC and exhibits inflammation that is mostly limited to colonic mucosa [206]. Multiple 
drug therapies tested on this model have been highly effective. Dexamethasone, a 
corticosteroid, when administered orally as 3mg/kg dose daily, appeared to inhibit goblet 
cell loss and leukocyte infiltration in this model [207].Other therapies tested on TCRα-/- 
mice include immunoglobulin G (with monoclonal auto-antibodies), chitin microparticles 
administered orally and carbon monoxide. The former can have an impact on B-cell 
deficient TCRα KO mice [197,208]. Chitin microparticles appear to suppress the 
production of IL-4 and TNFα and upregulates IFN-γ in mesenteric lymph nodes. The 
latter has shown to have an anti-inflammatory effect by suppressing IL-1β, IL-4 and 
TNFα and inducing IL-10 production [209]. Anti-IL-4 antibodies immunotherapy 
controls Th2-specific cytokine production, thereby suppressing the clinical and 
histological forms of colitis [197,210]. 
WASP
-/- 
mice develop spontaneous UC-like colitis at 6 months of age and are used to test 
the efficacy of WASP-expressing retrovirus [133,197]. Transduction of the virus prior to 
introducing into WASP-deficient haematopoietic stem cells irradiated mice resulted in the 
reduction of colitis. The control group of chimeric mice with retrovirus-transduced 
WASP-deficient hematopoietic cells showed signs of the development of the disease 
[197,211]. Colitis in WASP
-/-
 mice was treated with oral alkaline phosphatase [212,213], 
neutralisation of Il-4 by weekly anti-IL-4 injections [214] and subsequently a IL-10 
immunoglobulin fusion protein completely abrogated colitis in chimeric mice with 
WASP-deficient immune cells [215].  
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Mdr1a
-/-
 mice, lacking the multiple drug resistance 1a (Mdr1a) gene, have been useful in 
testing the efficacy of prophylactic use of broad spectrum antibiotics [197,216]. Mdr1a
-/-
 
mice, when raised in a germfree environment, are colitis free. The incidence of colitis in 
specific pathogen free raised Mdr1a
-/-
 mice is greatly reduced by the use of broad 
spectrum antibiotics [216]. Multiple polymorphisms have been identified in the Mdr1a 
locus in human UC [217].  
 
Targeted therapies were identified to regulate colitis severity in
 
IL-2
-/- 
mice. More severe 
colitis was observed in 2,4,6 trinitrophenol-ovalbumin-immunised IL-2
-/-
 mice than in the 
untreated mice [197].
 
However, when monoclonal antibodies were administered targeting 
αEβ7 along with 2,4,6 trinitrophenol-ovalbumin, the result was a reduction of colitis as 
well as a reduction of CD4
+ 
cells and IFN-γ in the lamina propria [218]. Green tea 
polyphenol extract in drinking water was used to reduce IFN-γ and TNF-α production, 
thereby improving the histological features of the spontaneous colitis in IL-2
-/- 
[219].   
 
Gαi2-/- mice have been utilised for testing therapeutic agents, resulting in amelioration of 
colitis. Acellular Bordetella pertussis, when injected into the peritoneal region of Gαi2-/- 
mice, resulted in upregulation of IL-10 in the gut, subsequently demonstrating a marked 
reduction in colitis [197,220]. Responsiveness to methyl prednisolone of ex vivo colon 
cultures of Gαi2-/- mice were alike to those of mice that had been orally treated with the 
same drug [221]. Ex vivo testing is a promising avenue in validating IBD therapeutic 
strategies. 
 
 
  
W. BASHEER 
GENETIC ABLATION OF Ccr6 CONFERS DIFFERENTIAL EXACERBATION IN A SPONTANEOUS COLITIS MODEL   104 
 
The IL-7 Tg strain, a model of UC, spontaneously develops acute colitis between 1–3 
weeks of age [133,222]. IL-7 has been identified as a candidate gene correlated with UC 
and up-regulation of the IL-7 protein expression maintains a long-term effect specifically 
on CD4+T cells in the mucosa of the colon [223]. This strain has been observed to utilise 
the IL-7Rα chain in order to orchestrate chronic colitis. This particular chain appears to 
be expressed only on CD4+ T cells. Blockade of IL-7R efficiently suppresses gut 
inflammation in adoptive transfer-induced models [224]. IL-7 Tg mice are considered 
suitable for studying T-cell-mediated colitis and are involved in the development of T-cell 
targeted therapeutics [197].  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
The TRUC (Tbet
-/-
XRag2
-/-
) colitis model is useful for investigating mechanisms such as 
the efficacy of antibiotics, T-regulatory cell infusion and TNF-α neutralisation to 
ameliorate colitis [225]. TGFβRIIDN displays both spontaneous differentiation of Th 
cells and multi-organ autoimmune inflammation, particularly IBD [226]. The 
C3H/HeJBir model develops spontaneous acute colitis, which is usually self-limiting. 
This model is utilised to assess the particular inhibition of inflammatory mediators and 
target molecules [227].  
 
Animal models provide the necessary platform for novel treatment strategies 
[133,197,198]. The choice of relevant mouse models is vital when exploring therapeutic 
strategies for specific diseases. Current treatments have been associated with 
immunosuppression to moderate the severity of inflammation and its long-term efficiency 
is important. Identification of the exact course of events leading to IBD has proved to be 
challenging as the available colitis models are induced either chemically or 
immunologically and these modes of induction have revealed contrasting results within 
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the mouse models. Hence, in the present study a new mouse model, namely Winnie x 
Ccr6
-/-
 mice, was generated and acquired a few interesting and significant findings. 
 
 Genetic ablation of Ccr6 results in differential expression in Winnie x Ccr6-/- 
colitis. 
 Ccr6 deficiency alters the inflammation pattern in the Winnie x Ccr6-/- colon, 
conferring both exacerbation and amelioration in the colonic segments. 
 
Expression of the genes Il-1β, Il-10, Il-23a, Il-22, Il-6, Tgfβ-1, Ccr6, and Ccl20 were 
studied in the colonic tissues of Winnie x Ccr6
-/-
 mice. Results from the gene expression 
studies in Winnie x Ccr6
-/- 
mice revealed an up-regulation of the gene for pro-
inflammatory cytokine IL-1β, in the absence of Ccr6, specifically in the proximal colon. 
Increased Il-1β expression in the Winnie x Ccr6-/- mouse model is similar to that reported 
in both UC and CD in humans [145,228]. In the Winnie mice distal colon, Il-1β is highly 
expressed and it was clearly evident from the findings in Winnie x Ccr6
-/-
 mice, that Il-1β 
gene expression was highly up-regulated specifically in the proximal colon, in the 
absence of Ccr6. Exacerbation of inflammation in the proximal colon was more 
pronounced in the Winnie x Ccr6
-/- 
phenotype than in the distal colon. Surprisingly, 
down-regulation of the Il-1β gene and reduction in the protein levels in the distal colon of 
Winnie x Ccr6
-/-
 mice reflected the histological outcome, suggesting a preferential 
production/release in the colonic segments attributed to the absence of Ccr6.  
With regard to CCR6 ligand expression, we identified an up-regulation of this chemokine 
ligand, suggesting that the CCL20
+
Th17 cells are present in the lamina propria of the 
Winnie x Ccr6
-/-
 mice proximal colon in high levels which interestingly revealed opposite 
patterns to Winnie mice colonic segments. This emphasises that Ccr6 is an important 
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factor in immune regulation, in line with the current literature [91,95]. The expression of 
Ccr6 is intrinsically driven by IL-23A and thus an expression of CCL20
+
Th17 cells in the 
intestinal epithelium and CCR6
+
 Tregs are involved in an intriguing loop of events. 
Previous studies have established that IL-23 is the key player in a Th17 generation and 
differentiation and is supposedly linked to Ccr6, as it is the surface receptor for Th17 
cells and is found in CD [229]. However, in the Winnie x Ccr6
-/- 
phenotype, Il-23a 
seemed unaffected by the absence of Ccr6. In Winnie x Ccr6
-/-
 mice, Tgfβ1 levels were 
down-regulated in the proximal and distal colon of Winnie x Ccr6
-/- 
mice, and Il-6 
expression was significantly up-regulated, indicating that Ccr6 is necessary and that it is 
involved in Th17 recruitment in colitis, concurrent with earlier studies [104]. 
A significant up-regulation of Il-22 and Il-10 expression in the distal colon of Winnie x 
Ccr6
-/- 
mice was identified and reflected the significant increase in IL-10 production in 
cultured T cells, validating the histological outcome of the phenotype. In the absence of 
Ccr6, the identified amelioration of colitis could possibly be attributed to Il-10. Findings 
from the gene expression, protein levels and clinical experiments all were similar to the 
histological examination of the distal colon, which mostly remained non-inflamed. The 
differential expression of Ccr6 was also identified in our immunological findings which 
clearly showed that there was a down-regulated expression in the CD4
+ 
FOXP3
+ 
Treg cell 
population and an up-regulation in the Ccr6
+ 
IL17
+ 
Th17 population in the draining lymph 
nodes which implies that in the absence of Ccr6 the CD4
+
 T cells take up an effector 
phenotype, given the favourable cytokine milieu, and influences the inflammatory process 
[52,56,230].  
In the absence of Ccr6 in Winnie x Ccr6
-/- 
mice, reduction of CD4
+ 
FOXP3
+ 
Treg cells 
indicated that Treg cells choose to facilitate CD4
+ 
IL17
+ 
T effector cells to accentuate 
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rather than suppress inflammation in selected sites of the colon, which is attributed to the 
flexibility in the CD4
+
T cells. Preferential induction of Il-10 by lamina propria 
macrophages and DCs facilitating Th17 cells was reported by previous studies [195] and 
the same was identified in our findings. Il-10 was expressed in the distal colon of our 
model, possibly induced by macrophages and assisting in restricting the inflammation in 
this part of the colon, suggesting that it could ameliorate if not for Ccr6. The decreased 
number of CD4
+
 FOXP3
+ 
Treg cells indicated that the CD4
+ 
T cells require Ccr6 as in its 
absence the immune cells and innate immunity moves towards augmentation of the 
disease. The inflammatory variance imparted due to the deficiency of Ccr6 in the Winnie 
x Ccr6
-/-
 mouse model is remarkable and, to our knowledge, it has not been demonstrated 
in any other IBD mouse model. The Winnie x Ccr6
-/- 
model has, in fact, demonstrated 
that the expression of Ccl20
+ 
Th17 cells corresponds to the inflammation in being 
portrayed as independent to Ccr6, which needs to be dissected with future experiments in 
this model and will effectively deliver better understanding with regard to the role of 
Ccl20 in the absence of Ccr6.  
The innate immune system plays a very important role in IBD pathogenesis and toll-like 
receptors (TLRs) play a key role in the mucosal immune system [231]. The regulation of 
Ccl20 by the innate immune system is not clearly defined, although the stimulation and 
release of this ligand into the peripheral blood mononuclear cells from the epithelium 
have been studied by using TNFα, IL-1α and IL-1β [90,93,232]. Skovdahl et al. [90] 
demonstrated the up-regulation of TLR3 in IBD, stating that there is an indication that 
pattern recognition receptors (PRRs) may play a key role in activation of the CCR6-
CCL20 axis in IBD. Multi-cytokine mediated inflammation, possibly directed towards a 
Th17 immune response, was demonstrated in our Winnie x Ccr6
-/- 
mice. In the absence of 
Ccr6 there exists a differential pattern of expression in the genes involved in the 
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inflammation process in the Winnie x Ccr6
-/- 
phenotype, and further studies are required 
to explore the biology of the CCR6-CCL20 axis.   
 The Winnie x Ccr6
-/-
  had been generated in order to understand the effects in the 
absence of the Ccr6 gene in an existing spontaneous chronic colitis model as Winnie mice 
display spontaneous distal colitis due to protein misfolding [43]. However, to the 
contrary, in Winnie x Ccr6
-/- 
mice we demonstrated exacerbated proximal colitis. This 
inflammation pattern was quite intriguing, and the causes of amelioration of distal colitis 
were unclear. Distribution of inflammation in the colonic segments observed in the 
Winnie x Ccr6
-/-
 mice was a significant finding, and it could possibly be attributed to 
various events, in the absence of Ccr6 in a spontaneous colitis model. Differences 
identified in the immune cell populations of mesenteric lymph nodes in the small intestine 
and large intestine was reported by Houston et al. [233]. The alterations in the populations 
with regard to the draining lymph nodes could possibly impact the outcome of the cells 
analysed from the MLNs.  
The obtained results suggest that Winnie x Ccr6
-/-
 mice have an increased IL-10 secretion 
which is thought to be a major contributor to the amelioration of distal colitis. Hence the 
IL-17/IL-23 pathway in colitis is disrupted and homeostasis is encouraged by the 
increased production of IL-10 along with the other pro-inflammatory cytokines such as 
IL-17 and IL-22. Thus homeostasis is conferred in an inflammatory phenotype, resulting 
in amelioration of distal colitis in Winnie x Ccr6
-/-
 mice. The T cell transfer model of 
colitis, where naïve T cells from Ccr6-deficient mice resulted in severe colitis, is the most 
studied model where it was demonstrated that the IL-10 producing Ccr6
+
 Treg cells, 
considered novel homing subsets of T cells, were indeed essential in order to confer 
protection [95]. 
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Development of the Ccr6
-/- 
mouse model was vital in understanding the relationship 
between Treg and Th17 cells, and to identify the immune modulation in the absence of 
Ccr6. Understanding the biological processes involved in the recruitment of T cell subsets 
and identifying dysregulations in these mouse models is important. Ccr6
-/- 
mice have
 
been 
used to model various autoimmune diseases and immune-mediated diseases [109,234], as 
they are involved in contrasting roles of both immune regulation and inflammation and, 
hence, they are used to study IBD pathology [137,140].  Ccr6-/- mice exhibited an altered 
the immune system, displaying a reduction in the Peyer’s patches and increased amounts 
of intraepithelial lymphocytes [49]. When colitis was induced by DSS it resulted in 
reducing the severity of the pathology and when induced by TNBS it conferred 
susceptibility to the otherwise resistant strain [87,95]. This evidence alerts us to the fact 
that in our study the exacerbation of the inflammation indicates that CCR6 is indeed an 
important factor in the intestinal pathology of colitis in mice.  
In a previous study, using the T cell transfer colitis model, the absence of CCR6 resulted 
in severe colitis and an increased production of IFN-γ producing T cells [95]. Findings 
from the present study revealed increased IFN-γ producing T cells in the Winnie x Ccr6-/- 
model compared to the Ccr6
-/-
 mice, and this suggests that the subsequent inflammation 
will be severe. However, this study observed regional differentiation and alteration in the 
inflammation pattern, and hence concludes that Ccr6 is more important to Tregs than 
Th17cells. Reboldi et al. [235] reported that Ccr6-dependent Th17 cells were recruited 
into the uninflamed central nervous system (CNS) in the case of induced experimental 
autoimmune encephalitis (EAE), where Ccl20 was produced in the choroid plexus 
epithelial cells, which happens to be the site of cerebrospinal fluid production. However, 
Th17 cells were reportedly the first activated T cell subset which proceeds to initiate a 
Ccr6-independent inflammatory response. This has been challenged by some researchers 
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who reportedly identified that Th17 cells recruitment was not impacted in Ccr6
-/- 
mice 
CNS, and the disease was thought to be initially delayed, although eventually displayed 
as an exacerbated clinical EAE [234,236].  
Our clinical findings seem to indicate that Ccr6 does confer exacerbation to the otherwise 
uninflamed colonic segment. Yamazaki et al. [91] identified that regulation of Ccr6 
expression was brought about by TGF-β, along with the transcription factors RORγt and 
RORα. Th17+ Ccr6+ Ccl20+ cells are induced synergistically by both TGF-β and IL-6 and 
requiring STAT3, RORγt, RORα and IL-21 in the process [237].
 
The Th17 subset is considered as a distinct subset of CD4
+ 
T cells, producing pro-
inflammatory cytokine IL-17 which is associated with the development of inflammation 
mainly in immune-mediated disorders such as Crohn’s disease, RA and psoriasis, along 
with many others [181,238,239]. Pro-inflammatory cytokines IL-21 and IL-22 are also 
produced by these CD4
+
 T cells, where IL-21 assists in restoring the balance between 
Th17 and T reg cells, and IL-22, a unique cytokine belonging to the IL-10 family, is 
associated with chronic inflammation [240,241]. Differentiation of mouse Th17 cells 
requires RORC, a transcription factor, in the presence of both IL-6 and TGF-β, further 
enhanced by TNF and IL-1β [181,242]. Th17 cells can be inhibited by cytokines such as 
IFN-γ and IL-4 belonging to Th1 and Th2 subsets respectively [243].  
It has been widely accepted that TGF-β inhibits most T cell responses and at the same 
time it is responsible for the induction of FOXP3
+ 
Treg cells. The conflicting role of 
TGF-β was identified and thought to be interesting, as it acts as an inducer of both pro-
inflammatory (Th17) and anti-inflammatory (T reg) cells, similar to the intriguing nature 
of the CCR6-CCL20 [114,117] chemokine axis. The relationship between TGF-β and the 
T cell subsets needs a better understanding as both Th17 and Treg cells have opposite 
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roles. Reportedly, in mice, T reg cells act as a basis for Th17 differentiation, while Xu et 
al. [244] reported that CD4
+
 CD25
+
 FOXP3
+
 T reg cells, in the presence of IL-6, can 
mould themselves into Th17 and this could be due to the plasticity of CD4
+ 
T cells [52]. It 
is possible that Ccr6 modulates this change of T reg cells and enhances the induction of 
Th17 cells. T reg cells attempt to suppress Th17 cells and seem to be resistant, and this 
leads us to consider that Tregs could possibly enhance Th17-mediated inflammation 
[108,181]. Hence, the role of Ccr6
+ 
Treg cells and Ccr6
+ 
Th17 cells in inflammatory 
diseases need better understanding.  
The CCR6-CCL20 axis has been established as being involved in mucosal immunity, 
although they are reported to be involved in opposing roles. Their involvement in the 
events of Th17 and T reg cells and B cell differentiation has been extensively researched. 
The variability in the experimental outcome observed in our study implies that the distal 
colon needs to be targeted for therapy in order for this to be considered. CCR6 is a 
potential target for therapy in many autoimmune diseases and the availability of tissue-
specific knockout mice is vital. Development of the Ccl20
-/- 
mouse model will aid in the 
understanding of disease pathogenesis. The exact mechanism of CCR6 in IBD remains 
elusive and the specific role of CCR6-CCL20 in IBD is unclear. Nevertheless, with the 
aid of research findings from the present study, we conclude that Ccr6 has the ability to 
skew the disease progression from inflammation to homeostasis.  
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6.1 Summary 
 
This study is significant and, to our knowledge, it is the first to examine the role of Ccr6 
in inflammation, associated with a naturally occurring spontaneous colitis in humans. 
Unlike other contrived models, the Winnie x Ccr6
-/-
 model demonstrated proximal colitis 
due to an SNP simulating a clinical scenario. The present study clearly defines the 
dichotomy of Ccr6 in Winnie x Ccr6
-/- 
mice colitis. The Winnie x Ccr6
-/- 
mice
 
phenotype 
was explored based on the clinical, histological, molecular and immunological aspects. 
Differential patterns of inflammation were observed in regions of the Winnie x Ccr6
-/- 
colon. Increased expression of IL-1β indicates an exacerbation of inflammation in the 
proximal colon to the mid-colon region. The decreased expression of IL-10 suggests 
amelioration of inflammation in the distal colonic region. Our findings document the 
clinical and histological changes due to the genetic ablation of Ccr6 which were 
supported by molecular and cytokine expressions of both IL-10 and IL-1β. 
Immunological assessments confirmed the reduction of Ccr6
+
 FOXP3
+
 Treg cells and an 
increase in the Ccr6
+ 
Th17 subpopulation in Winnie x Ccr6
-/- 
mice which further suggests 
that the absence of Ccr6 mediates a Th17 mucosal response. Distribution of inflammation 
in the different colonic segments is a key finding in the present study.  
 
6.2 Future directions   
 
There are a few limitations in the present study and hence further studies using larger 
sample size, isolation of MLNs specific to colonic segments, mucosal enumeration of T 
regs, along with the other immune cells and evaluation of their functional aspects will be 
useful in identifying the specific role of Ccr6 in Winnie x Ccr6
-/- 
colitis. In addition, 
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studies directed towards distribution, localisation of CCL20 and identification of CCR6 as 
a biomarker can further improve the understanding of the current mouse model, thereby 
providing vital clues in solving the IBD puzzle. Further research is needed to identify the 
exact course of events which causes the CCR6-CCL20 chemokine pair to switch between 
Th17 and Treg cells, specifically in colitis.  
From a therapeutic perspective of IBD, the current conventional therapies involve the use 
of anti-inflammatory drugs such as aminosalicylates, corticosteroids, cyclosporine and 
biological therapies including monoclonal antibodies. The dendritic cell populations 
identified in different regions of the draining mesenteric lymph nodes could possibly 
regulate the outcome of the immune responses and assist in developing tissue-specific 
therapies. The concept of chemokine-targeted therapy for IBD is now being investigated 
widely. The CCR6-CCL20 pair is of great interest in autoimmune diseases such as 
psoriasis, RA and EAE, and is currently being researched as a possible therapeutic target.  
In future, immunoregulatory therapy could replace the current immunosuppressive 
concept, and could potentially open a new myriad of therapeutic target options for IBD. 
The research findings from our Winnie x Ccr6
-/- 
mouse model indicates that precise 
identification of the Ccr6 role in colitis will enable a step closer towards a comprehensive 
understanding of inflammatory bowel disease in humans, which will provide great 
translational value for future research in the field of IBD.  
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